<table>
<thead>
<tr>
<th><strong>Editorial Board</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Global Journal of Medical Research</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Apostolos Ch. Zarros</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DM, Degree (Ptychio) holder in Medicine, National and Kapodistrian University of Athens MRes, Master of Research in Molecular Functions in Disease, University of Glasgow FRNS, Fellow, Royal Numismatic Society Member, European Society for Neurochemistry Member, Royal Institute of Philosophy Scotland, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. William Chi-shing Cho</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph.D., Department of Clinical Oncology Queen Elizabeth Hospital Hong Kong</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Alfio Ferlito</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor Department of Surgical Sciences University of Udine School of Medicine, Italy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Michael Wink</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph.D., Technical University Braunschweig, Germany Head of Department Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Jixin Zhong</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Department of Medicine, Affiliated Hospital of Guangdong Medical College, Zhanjiang, China, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH 43210, US</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Pejcić Ana</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Assistant Medical Faculty Department of Periodontology and Oral Medicine University of Nis, Serbia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Rama Rao Ganga</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MBBS MS (University of Health Sciences, Vijayawada, India) MRCS (Royal College of Surgeons of Edinburgh, UK) United States</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Izzet Yavuz</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MSc, Ph.D., D Ped Dent. Associate Professor, Pediatric Dentistry Faculty of Dentistry, University of Dicle Diyarbakir, Turkey</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Sanguansak Rerksuppaphol</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Department of Pediatrics Faculty of Medicine Srinakhrinwirot University NakornNayok, Thailand</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Ivandro Soares Monteiro</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>M.Sc., Ph.D. in Psychology Clinic, Professor University of Minho, Portugal</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dr. Sanjay Dixit, M.D.</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Director, EP Laboratories, Philadelphia VA Medical Center Cardiovascular Medicine - Cardiac Arrhythmia Univ of Penn School of Medicine Web: pennmedicine.org/wagform/MainPage.aspx?</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Antonio Simone Laganà</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>M.D. Unit of Gynecology and Obstetrics Department of Human Pathology in Adulthood and Childhood “G. Barresi” University of Messina, Italy</td>
</tr>
<tr>
<td>Name</td>
</tr>
<tr>
<td>-----------------------</td>
</tr>
<tr>
<td>Dr. Han-Xiang Deng</td>
</tr>
<tr>
<td>Dr. Roberto Sanchez</td>
</tr>
<tr>
<td>Dr. Feng Feng</td>
</tr>
<tr>
<td>Dr. Hrushikesh Aphale</td>
</tr>
<tr>
<td>Gaurav Singhal</td>
</tr>
<tr>
<td>Dr. Pina C. Sanelli</td>
</tr>
<tr>
<td>Dr. Michael R. Rudnick</td>
</tr>
<tr>
<td>Dr. Seung-Yup Ku</td>
</tr>
<tr>
<td>Santhosh Kumar</td>
</tr>
<tr>
<td>Dr. Aarti Garg</td>
</tr>
<tr>
<td>Name</td>
</tr>
<tr>
<td>---------------------------</td>
</tr>
<tr>
<td>Sabreena Safuan</td>
</tr>
<tr>
<td>Getahun Asebe</td>
</tr>
<tr>
<td>Dr. Suraj Agarwal</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Osama Alali</td>
</tr>
<tr>
<td>Prabudh Goel</td>
</tr>
<tr>
<td>Raouf Hajji</td>
</tr>
<tr>
<td>Surekha Damineni</td>
</tr>
<tr>
<td>Arundhati Biswas</td>
</tr>
<tr>
<td>Rui Pedro Pereira de Almeida</td>
</tr>
<tr>
<td>Dr. Sunanda Sharma</td>
</tr>
<tr>
<td>Shahanawaz SD</td>
</tr>
<tr>
<td>Dr. Shabana Naz Shah</td>
</tr>
<tr>
<td>Vaishnavi V.K Vedam</td>
</tr>
<tr>
<td>Tariq Aziz</td>
</tr>
</tbody>
</table>
Contents of the Issue

i. Copyright Notice
ii. Editorial Board Members
iii. Chief Author and Dean
iv. Contents of the Issue

1. Evaluation of the Quality Indicators of the Drug "Bralekord" Solution for Infusions. 1-6
2. From the Histological Model to the Mutational Model: The Study of Heavy Metals and Other Substances in New Antineoplastic Therapies. 7-9
3. Qualitative Studies on the Factors Influencing the Utilisation of Products Labelled "Food for Special Medicinal Use" (FSMP). 11-20

v. Fellows
vi. Auxiliary Memberships
vii. Preferred Author Guidelines
viii. Index
Evaluation of the Quality Indicators of the Drug "Bralekord" Solution for Infusions

By Azamat Ibragimovich Abdunazarov & Azizakhon Dilshodovna Tashpulatova
Tashkent Pharmaceutical Institute

Abstract- The results of standardization and quality control of the drug "Bralecord" solution for infusions are given, according to such quality indicators as: description, authenticity, transparency, color, pH, mechanical inclusions, impurities, osmolality.

Keywords: quality indicators, standardization, quality control, injection solution, pharmacopoeia, normative document.

GJMR-B Classification: NLM: QV 778
Evaluation of the Quality Indicators of the Drug "Bralekord" Solution for Infusions

Azamat Ibragimovich Abdunazarov & Azizakhon Dilshodovna Tashpulatova

Abstract- The results of standardization and quality control of the drug "Bralecord" solution for infusions are given, according to such quality indicators as: description, authenticity, transparency, color, pH, mechanical inclusions, impurities, osmolality.

Keywords: quality indicators, standardization, quality control, injection solution, pharmacopoeia, normative document.

I. INTRODUCTION

Processes of globalization of the pharmaceutical market; a high level of competition, as a result of which there is a shift in competitiveness factors from the level of the product to the level of the organization as a whole; an increase in the number of interactions in the process of drug circulation; social responsibility of business and its customer orientation; the characteristics of pharmaceutical products, as well as the requirements of regulatory legal acts, are the main reasons for the development and implementation of quality assurance systems or, at a higher level of development, quality management in the implementation of pharmaceutical activities.

An essential condition for the functioning of the sphere of drug circulation, as well as one of the main mechanisms for ensuring the required level of quality and safety of pharmaceutical products and services in the interests of the consumer, is the standardization procedure [1-2].

Standardization is the activity of establishing rules and characteristics for the purpose of their voluntary reuse, aimed at achieving orderliness in the areas of production and circulation of products and increasing competitiveness.

To date, one of the pressing issues of healthcare in the Republic of Uzbekistan is the provision of vital drugs that meet the high requirements of modern medicine. The quality of infusion solutions must meet the stringent requirements of modern standards. Only in the conditions of pharmaceutical production, it is possible to eliminate the influence of the human factor as much as possible and introduce multi-stage quality control. The control of the main indicators of the quality of the finished product and the parameters of the technological process plays an important role in obtaining drugs of guaranteed quality. An increased risk in the parenteral route of administration of large volume solutions (100 ml or more) or infusion solutions causes high requirements for their quality [3].

Quality standards for medicines should ensure the development of a high quality, effective and safe medicine, and should be revised in a timely manner, taking into account new achievements in medical, pharmaceutical and other sciences and the requirements of leading foreign pharmacopoeias.

An objective assessment of the quality of medicines depends not only on the merit of the methods, but also on the fact that their use in different laboratories allows obtaining identical results. This is ensured by the standardization of quality assessment methods, the preparation of solutions, reagents and indicators, the standardization of instruments, etc. The standard as ND establishes a set of norms or requirements for the object of standardization [4].

Bralecord is a combined drug containing in its composition: sodium citicoline, L-arginine hydrochloride, levocarnitine, used as a nootropic and metabolic agent.

Purpose of the study. The purpose of these studies is to develop methods for assessing the quality and establishing indicators of the quality of the combined drug "Bralecord" solution for infusion.

II. EXPERIMENTAL PART

a) Materials and research methods

As objects of study, 5 series of pilot samples of the drug "Bralecord" solution for infusions were used. During the study, solvents, reagents and consumables from MERCK (Germany) were used. The following auxiliary equipment was also used in the tests: magnetic stirrers, BP-310S electronic analytical balance from Sartorius (Germany), HS 32 AC sterilizer with automation, Seven Easy pH meters from Mettler Toledo (Switzerland) and 766 Calimatic Knick (Germany), Julabo water thermostat (Germany), Osmomat 010 type osmometer, Gonotek (Germany), PAMAS SVSS liquid particle counters (Germany).

b) Results and its discussion

The evaluation of the quality indicators of the study drug was carried out in accordance with the modern requirements of the national and foreign pharmacopoeias [5-7], as well as in accordance with the general technical regulation on the safety of medicines [8] in terms of such indicators as:
description, authenticity, transparency, color, pH, mechanical inclusions, impurities, osmolality, sterility, bacterial endotoxins, abnormal toxicity, quantitation.

The initial stage of work is organoleptic control, which is a mandatory type of control and consists in checking the medicinal product in terms of appearance, smell, mixing uniformity, and the absence of mechanical impurities in liquid dosage forms.

c) Description

The drug should be a clear, colorless or slightly yellowish solution (visual method). All studied five series of the drug meet the requirements of the pharmacopoeia.

d) Authenticity

Identification was carried out by a chemical method using qualitative reactions to the main components of the drug: sodium citicoline, arginine, levocarnitine and chlorides.

Sodium citicoline was determined by the spectrophotometric method at an absorption maximum at 280 nm. 1.0 ml of the drug was placed in a volumetric flask with a capacity of 100 ml, the volume of the solution was brought to the mark with a 0.01 mol/l solution of hydrochloric acid and mixed. 10 ml of the resulting solution was placed in a volumetric flask with a capacity of 50 ml, the volume of the solution was brought to the mark with a 0.01 mol/l solution of hydrochloric acid and stirred (test solution).

The optical density of the resulting solution was measured on a spectrophotometer at the absorption maximum at a wavelength of 280 nm in a cuvette with a layer thickness of 10 mm, using a 0.01 mol/l hydrochloric acid solution as a reference solution. In parallel, the optical density of the RSO solution of sodium citicoline was measured at the same wavelength.

Arginine. 15 ml of water was added to 5 ml of the preparation. To 2 ml of the resulting solution was acidified 1 ml of α-naphthol solution and 2 ml of a mixture of equal volumes of 3% sodium hypochlorite solution and water; a red color is formed.

Levocarnitine. 2 ml of the drug was transferred into a test tube, 5 ml of 1 mol/l hydrochloric acid solution and a few drops of ammonium rheinecate solution were added, and a red-violet precipitate formed.

Preparation of ammonium rheinecate solution: about 500 mg of ammonium rheinecate was mixed with 20 ml of water, shaken periodically for 1 hour and filtered. The solution is used within 2 days.

Chlorides. 2.0 ml of the drug was acidified with dilute nitric acid, 0.4 ml of a silver nitrate solution was added, and a white curdled precipitate (chlorides) was formed upon standing.

All studied five batches of the drug confirmed the presence of citicoline sodium, arginine, levocarnitine and chlorides in the solution of the study drug.

Transparency. The solution of the drug should be transparent compared to water for injection.

Chromaticity was determined in accordance with the European or British Pharmacopoeia. It was found that the color of the preparation should not be more intense than the reference solution Y7.

The pH was set potentiometrically. It was found that the pH of the drug solution should be in the range from 5.0 to 7.5.

All studied five batches of the drug met the requirements of pharmacopoeias in terms of mandatory indicators: transparency, color, pH.

Foreign impurities

Citicoline sodium. High performance liquid chromatography method.

Chromatographic system and determination conditions

Instrument liquid chromatograph “ShimadzuLC-6A”

Steel column, size 30 cm x 4.0 mm

Octadeceylsilane filler chemically bonded to porous silica gel or ceramic microparticles 10 µm in diameter (Li, USP)

Flow rate 2 ml/min

Detection 275 nm

Injection volume 20 µl

A column filled with octadceylsilane silica gel and phosphate buffer solution was used (equal volumes of 0.1 mol/l potassium dihydrogen phosphate and tetrabutylammonium phosphate solution were mixed, the pH value of 0.01 mol/l tetrabutylammonium hydroxide was adjusted to 4.5 with phosphoric acid), methanol (95 : 5) as mobile phase.

1 ml of the drug was carefully transferred into a 10 ml volumetric flask and diluted with water to the mark (test solution).

Dissolve the required amount of citicoline sodium RSO and levocarnitine RSO in water to obtain a solution of 1.045 mg/ml sodium citicoline and 2.0 mg/ml levocarnitine (control solution).

Transfer 1.25 ml of the control solution to a 100 ml volumetric flask. Dilute to the mark with water and mix well (system suitability solution).

Introduced 20 µl of reference solution 1 into the column. The dilutions were adjusted so that the main maximum in the chromatogram was 20-25% of the full scale of the chart. Add 20 µl of each test solution, system suitability solution, and control solution separately to the column. Chromatography was continued at 2.5 times the retention time of the citicoline peak.

Calculations:

The content of an individual non-identifying or identifying impurity, in percent:
More than 0.5%, total impurities: no more than 2.0%. Individual impurities: no more than 0.5%, and the total impurity - no more than 2.0%. All five batches of the study drug met the established norm.

Substances detected by ninhydrin. The determinations are carried out by thin layer chromatography.

System suitability solution: 0.4mg/ml each of arginine hydrochloride and L-lysine hydrochloride with water

Sample solution: 10 mg/ml RSO arginine hydrochloride with water

Standard solution: dilute 1 ml of sample solution with water to 100 ml. Dilute 5 ml of the resulting solution with water to 10 ml (0.05 mg/ml)

Note: The concentration of the solution is approximately 0.5% of this sample solution.

Test solution: 100 µl of the drug is added to 320 µl of water (10 mg/ml)

Chromatography System Mode: TLC

Adsorbent: 0.25 mm layer of chromatographic silica gel mixture

Applied sample volume: 5 µl

Mobile solvent system: isopropyl alcohol and ammonium hydroxide (70:30)

Nebulizer: 2 mg/ml ninhydrin in butyl alcohol and 2N acetic acid (95:5)

Drying: at a temperature from 100 °C to 105 °C until complete removal of ammonia. The plate is sprayed with a solution of 2 mg/ml ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5) and heated at 100°C to 105°C for 15 minutes. Examine the plate under daylight. The system suitability chromatogram shows two completely separated spots.

Norm: any spot, except for the main one, should not be more intense than the main spot on the chromatogram of the standard solution (0.5%). Individual impurities: no more than 0.5%, total impurities: no more than 2.0%.

The results of the analysis are considered reliable if two clearly separated spots appear on the chromatogram of the system suitability solution.

All studied five series of the drug corresponded to the established norm.


Reagents: 2M sodium hydroxide solution. Solution A: 6.81 g of KH2PO4 are dissolved in 800 ml of water, 2M sodium hydroxide solution is added to obtain a pH of 4.7, the volume of the solution is adjusted to the mark with water and mixed; Acetonitrile.

Chromatography conditions. Column: Aminopropyl methyethylsilangel (USP L8), 250x4.6mm, 5 µm; Column temperature: 30°C±1°C; UV detector: 205nm. Mobile phase: A mixture of 35 volumes of solution A and 65 volumes of acetonitrile; flow rate: 1.0ml/min; injection volume: 25µl.

Standard solutions and test solution are introduced into the chromatograph and chromatograms are recorded within 20 minutes. The sensitivity of the system is determined by the height of the main peak on the chromatogram of the standard solution (c), which is at least 20% of the full scale of the recording device. The test is considered invalid if the resolution between the peaks of levocarnitine and levocarnitine impurity A in the chromatogram of the standard solution (c) is 0.9. On the chromatogram of the test solution: the area of any peak of levocarnitine impurity A is not more than the main peak of the chromatogram of the standard solution (c) (1%); the area of any peak, except for the main peak and the peak of levocarnitine impurity A, does not exceed the area of the main peak in the chromatogram of the standard solution a (0.2%); the sum of the areas of all peaks, except for the main peak and the peak of impurity A, does not exceed 2.5 times the area of the main peak in the chromatogram of standard solution a (0.5%).

Preparation of standard solution "a". 100 mg of the drug solution is transferred into a 100 ml volumetric flask, the volume is adjusted to the mark with solution A. 1 ml of the resulting solution is diluted to 10 ml with the same solvent (0.2%).

Preparation of standard solution "c". 20.0 mg of the working standard sample of levocarnitine impurity A is dissolved in water, the solution is adjusted with water to 100 ml. 2.5 ml of the resulting solution is diluted to 10 ml with solution A (1.0%).

Preparation of standard solution "c". 10 mg of the working standard sample of levocarnitine impurity A is dissolved in water and diluted with water to 25 ml and 2.5 ml of the resulting solution is diluted to 10 ml with solution A.

Preparation of standard solution "d". Dissolve 100 mg of the working standard of levocarnitine in 10 ml of standard solution C.

Preparation of the test solution. 2.5 ml of the preparation solution is transferred into a volumetric flask with a capacity of 100 ml and the volume is brought to the mark with solution A.

Norm: impurities A should be no more than 1.0%; other impurities - no more than 0.2%; the sum of impurities, except for impurity A - no more than 0.5%. 

\[
X = \frac{AT \times 100\%}{As}
\]

where: AT = Peak area of an individual impurity in the test solution

As = Sum of all peak areas in control solution

The results of the analysis are considered reliable if two clearly separated spots appear on the chromatogram of the system suitability solution.
According to the results of the studies, all five series of the drug under study corresponded to the established norm.

Osmolality. The determination of the osmolality of the solution is carried out by the cryoscopic method using a Beckmann thermometer. The determination of the freezing point is carried out on the installation shown in Figure 1.

The main part of the setup is a test tube with a side branch. Its upper opening is tightly closed with a cork through which the Beckmann thermometer and a wire stirrer pass, one end of which is bent in the form of a ring freely covering the lower part of the thermometer. This test tube is inserted into a wider test tube, which acts as an air jacket that prevents the liquid from cooling too quickly. The assembled apparatus is placed in a Bunsen beaker, which is filled with a cooling mixture before the experiment.

The role of the cooling mixture is performed by ice chips, to which crystalline sodium chloride is added to reduce the temperature. A stirrer is used to stir the cooling mixture. The temperature of the cooling mixture should be (4-5)°C below the freezing point of the test liquid.

The zero point of the instrument is set to water for injection. The instrument is calibrated using standard sodium chloride solutions. The determination is carried out three times and the average value is taken.

As needed, prepare standard solutions based on the data in Table 1.

To determine the freezing point of a solvent or a test solution, 28-30 g of liquid is placed into an inner small test tube through a side hole, a stirrer and a Beckmann thermometer are also placed here. This tube is placed through an air jacket into the cooled mixture and the test liquid is evenly mixed by raising and lowering the stirrer. When determining the freezing point of a liquid, the mercury column in the thermometer begins to fall as the liquid cools. Usually, before freezing, the liquid is supercooled, and the temperature of the liquid drops below the freezing point. As soon as the crystallization process begins, the temperature of the solution rises beyond the freezing point.

The increase in temperature occurs due to the release of open heat of solidification.

After that, the test tube is removed from the liquid, the crystals are melted by heating the test tube with the hand, and the determination is repeated again. The experiment is carried out three times. The discrepancy between the definitions should be no more than 0.01°C. In case of hypothermia, it is necessary to add a solvent crystal to the liquid. The accuracy of determination with this method is +5%.

<table>
<thead>
<tr>
<th>Mass of sodium chloride, in grams per 1 kg of water</th>
<th>Actual osmolarity (mosm/kg)</th>
<th>Theoretical osmolarity (ideal)</th>
<th>Molar osmotic coefficient (mosm/kg)</th>
<th>Freezing temperature drop ΔT zam.</th>
</tr>
</thead>
<tbody>
<tr>
<td>3,087</td>
<td>100</td>
<td>105,67</td>
<td>0,9463</td>
<td>0,186</td>
</tr>
<tr>
<td>6,260</td>
<td>200</td>
<td>214,20</td>
<td>0,9337</td>
<td>0,372</td>
</tr>
<tr>
<td>9,463</td>
<td>300</td>
<td>323,83</td>
<td>0,9264</td>
<td>0,558</td>
</tr>
<tr>
<td>12,684</td>
<td>400</td>
<td>437,07</td>
<td>0,9215</td>
<td>0,744</td>
</tr>
<tr>
<td>15,916</td>
<td>500</td>
<td>544,66</td>
<td>0,9180</td>
<td>0,930</td>
</tr>
<tr>
<td>19,147</td>
<td>600</td>
<td>655,24</td>
<td>0,9157</td>
<td>1,116</td>
</tr>
<tr>
<td>22,380</td>
<td>700</td>
<td>765,86</td>
<td>0,9140</td>
<td>1,302</td>
</tr>
</tbody>
</table>
**The device of the Beckman device:** A - a vessel for the test solution; B - Beckman thermometer; B - stirrer; G - container with coolant; D - thermometer for measuring the temperature of the cooling mixture.

Before each measurement, the tube with the lateral process is rinsed with the solution intended for the study, and the measurement is also made with the test samples.

The instrument is ready to measure the test product if the value obtained for the calibration solutions is within two values of the calibration scale. To reduce the error and check the reproducibility, it is recommended to repeat measurements with several samples from the same sample, averaging the results. The measurement error should not exceed ±2%.

The calculation of osmolality is carried out according to the following formula:

$$S_{\text{oosm}, \text{mOsmol/kg (mOsmol/\text{l})}} = \frac{(T_2-T_1) \times 1000}{1.858},$$

where: 1.858 is the molar cryoscopic constant of water, corresponding to the decrease in freezing point that occurs as a result of dissolution

1 mole of a substance in 1 kg of water;
1000 - Conversion factor osm/kg to mosm/kg;
T₂ - freezing point of pure solvent (OC);
T₁ is the freezing point of the solution (OC).

Based on the measurements carried out, it was found that the osmolality should be in the range from 410 mOsmol/kg to 590 mOsmol/kg. All studied five series of the drug corresponded to the established norm.

**Mechanical inclusions:** Mechanical inclusions in dosage forms for parenteral use are extraneous mobile insoluble particles, with the exception of gas bubbles, accidentally present in drug solutions. The test for the presence of visible and invisible particulate matter is intended for visual evaluation of liquid parenteral dosage forms, including infusion solutions, and is a mandatory pharmacopoeial quality indicator.

Based on the foregoing, as a result of the research, visible and invisible mechanical particles were determined. To detect visible particles in accordance with the SP RUz., Eur.F., 2.9.20, OFS 42 Uz-0006-3341-2018, during visual inspection, the test preparation should not contain visible particles (visible particles should be absent).

To detect invisible particles in accordance with the SP RUz., Eur.F., 2.9.19, OFS 42 Uz-0005-3340-2018, invisible particles per 50 ml and 100 ml bottle for particles ≥ 25 microns should be no more than 600 pieces, for particles ≥10 microns should be no more than 6000 pieces (Ev.F., 2.9.19, OFS 42 Uz-0005-3340-2018).

For 200 ml vial:

<table>
<thead>
<tr>
<th>Particle size</th>
<th>Number of particles in 1 ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 microns or more</td>
<td>Not more than 25 h/ml</td>
</tr>
<tr>
<td>25 microns or more</td>
<td>Not more than 3 h/ml</td>
</tr>
</tbody>
</table>

All studied five series of the drug corresponded to the established norm in terms of "mechanical inclusions".

The results of studies on the quality indicators of the drug "Bralecord" solution for infusion are presented in table 2.

**Table 2:** Research results on some quality indicators drug "Bralecord" solution for infusion

<table>
<thead>
<tr>
<th>The name of indicators</th>
<th>Norms</th>
<th>Series 1</th>
<th>Series 2</th>
<th>Series 3</th>
<th>Series 4</th>
<th>Series 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description</td>
<td>Clear, colorless or slightly yellowish solution.</td>
<td>Corresponds</td>
<td>corresponds</td>
<td>corresponds</td>
<td>corresponds</td>
<td>corresponds</td>
</tr>
<tr>
<td>Authenticity</td>
<td>SF-metry, qualitative reactions confirmed confirmed confirmed confirmed confirmed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transparency</td>
<td>The drug must be transparent transparent transparent transparent transparent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chroma</td>
<td>The color of the preparation should not be more intense than the reference solution Y₇ no more intense than reference solution Y₇ no more intense than reference solution Y₇ no more intense than reference solution Y₇ no more intense than reference solution Y₇</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>5.0-7.5</td>
<td>6.05</td>
<td>6.10</td>
<td>6.08</td>
<td>6.12</td>
<td>6.02</td>
</tr>
</tbody>
</table>
### Foreign matter:

<table>
<thead>
<tr>
<th>Component</th>
<th>Maximum Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citocline sodium</td>
<td>no more than 0.5%</td>
</tr>
<tr>
<td>Individual impurity total impurity</td>
<td>no more than 2.0%</td>
</tr>
<tr>
<td>Levocarnitine admixture A: others: the sum of impurities, except for impurity A:</td>
<td>no more than 1.0%</td>
</tr>
<tr>
<td>Substances detected by ninhydrin</td>
<td>no more than 0.5%</td>
</tr>
<tr>
<td>Osmolality</td>
<td>410-590 mosmol/l</td>
</tr>
<tr>
<td>Mechanical inclusions (visible)</td>
<td>missing</td>
</tr>
<tr>
<td>Mechanical inclusions (invisible)</td>
<td>corresponds</td>
</tr>
</tbody>
</table>

#### III. Conclusion

On the basis of the conducted experimental studies, the main indicators of the quality of the drug "Bralecord" solution for infusions were established in terms of: description, authenticity, transparency, color, pH, impurities, osmolality, mechanical inclusions. The limits of their normalization in accordance with the pharmacopoeias have been established. Approved quality indicators are included in the regulatory documentation for the study drug.

### References

3. Moiseeva E.V. "Ensuring the quality of infusion solutions in terms of "Mechanical inclusions" dissertation abstract for the degree of candidate of pharmaceutical sciences 15:00:01, RF, 2004.
From the Histological Model to the Mutational Model: The Study of Heavy Metals and Other Substances in New Antineoplastic Therapies

By Pasquale Ruffolo, Osvaldo Acquaviva, Pierpaolo Capece, Ferdinando Mazzei, Bruno Ruffolo, Manuela Panunzio, Alessandra Paraggio & Andrea Ruffolo

Abstract- The study of genetic mutations in tumours changes the therapeutic approach; in fact, we move into a different advanced and strategic phase by entering personalized precision medicine and shifting the focus from the tissue study of the tumour to the modification and proliferation of neoplastic cells. The therapeutic programs, especially in oncology, are changing. We are in a phase of transition from the histological model to the model of genetic mutation (mutation). When a person's immune defences do not respond to a disease it is because the body cannot produce or activate specific lymphocytes and antibodies against that disease. This causes of a lack of therapeutic response or recurrence of the disease.

Keywords: tumour disease, therapeutic response, complications, genomic modification, genomic and genetic tests, trace elements, immune response, nutritional supplementation, heavy metals, dioxins, hyperglycaemia, and hyperinsulinemia.

GJMR-B Classification: NLM Code: QZ 200
From the Histological Model to the Mutational Model: The Study of Heavy Metals and Other Substances in New Antineoplastic Therapies

Pasquale Ruffolo a, Osvaldo Acquaviva a, Pierpaolo Capece a, Ferdinando Mazzei b, Bruno Ruffolo y, Manuela Panunzio x, Alessandra Paraggio x & Andrea Ruffolo y

Abstract - The study of genetic mutations in tumours changes the therapeutic approach; in fact, we move into a different advanced and strategic phase by entering personalized precision medicine and shifting the focus from the tissue study of the tumour to the modification and proliferation of neoplastic cells. The therapeutic programs, especially in oncology, are changing. We are in a phase of transition from the histological model to the model of genetic mutation (mutation). When a person's immune defences do not respond to a disease it is because the body cannot produce or activate specific lymphocytes and antibodies against that disease. This causes a lack of therapeutic response or recurrence of the disease. A fundamental role is played by genomic tests, which are carried out directly on the neoplastic tissue and other modifies tissues, and the dosage of toxic substances (heavy metals, dioxins, furans, PCBs, etc.) analysed ‘primarily’ in the tumour and subsequently in the various biological matrices (tissues, modified, blood, urine, hair, nails, breast milk, saliva, etc.) as well as genetic tests. A significant role is a search for toxic substances and therapeutic integration of trace elements (mercury, lead, cadmium, selenium, zinc, cobalt, iron, and manganese) beneficial for cellular metabolism, especially for defence mechanisms, absent or deficient in these patients, such as Copper, Selenium, Zinc, Cobalt, Iron, and Manganese to improve or modify a lack of therapeutic response. Another parameter to consider is hyperglycaemia in diabetic subjects, which according to various scientific research, is considered a personal risk factor not so much in the formation phase of the neoplastic disease, but in the healing response phase. Keywords: tumour disease, therapeutic response, complications, genomic modification, genomic and genetic tests, trace elements, immune response, nutritional supplementation, heavy metals, dioxins, hyperglycaemia, and hyperinsulinism.

INTRODUCTION

Environmental pollution is today one of the major global problems with significant repercussions on human health. Despite this, little has been done to highlight the possible correlations between the different forms of pollution and the many related diseases, especially neoplastic ones. Unfortunately, little attention is paid to the importance of having a healthy, complete, and balanced diet to prevent neoplastic and chronic-degenerative diseases and to support the various therapeutic approaches. In this context, Nutrigenomics plays a fundamental role, which studies how nutrients can induce a modification or suppress genetic expressions, consequently acting on the individual phenotype. Nutrition (www.cestaecologia.it), with the possible introduction of toxic substances and a few substances useful for our body's defence mechanisms, such as vitamin D and vitamin C as well as Zinc and Copper, etc., as well as the environment in which we live, both due to soil, water and atmospheric pollution and the presence of electromagnetic fields and industrial sites (Sima Study; Rapporti ISTISAN 10/22, Ambiente salute, www.iss.it), can affect our DNA. Among the toxic substances with which we come into contact, both for environmental pollution and food, we have taken into consideration some dioxins because they are linked to immune defence deficits since they cause a reduced production of B and T lymphocytes as well as the PAHs which especially damage the lungs and nervous system.

We must start from the assumption that the genome is not a rigid structure, but interacts dynamically and evolutionary with the environment, so that pollution, global warming, and climate change will bring about phenotypic changes as an expression of the new genetic, with loss of biodiversity, but also of fertility. The many energy sources, now used for decades, further contribute to polluting our environment by acting accordingly on the genetic structure. A world that evolves with little respect for the environment will always make recent changes to our DNA which unfortunately can hardly be co-managed or controlled by the many increasingly current therapeutic approaches, denying us the right to health if there is no due respect for the
environment, we live in. In this article, our main objective is to analyse the presence in cancer patients, not only of nutritional deficiencies, but also of food toxicity that causes the accumulation of toxic substances that act by modifying, reducing, or blocking the immune response. For this reason, we must start from the analysis of the genetic mutations of tumours, changing the therapeutic approach; in fact, we move from the histological study of the tumour to a different advanced and strategic phase, entering a personalized precision medicine, shifting the focus to genetic modifications and neoplastic cell proliferation. The therapeutic programs, especially in oncology, are changing, as we are in a phase of transition from the histological model to the model of genetic mutation, called mutational model. To this new diagnostic model, according to our studies, it is essential to add the in-depth analysis of certain substances, such as heavy metals, dioxins, PCBs, etc., in the tumour and in the biological matrices and which can reduce or modify the therapeutic response. When a person's immune defences do not respond to a specific disease, it is because the body cannot produce or activate specific lymphocytes and antibodies against that disease. This causes the lack of therapeutic response or recurrence of the disease. A fundamental role is played by genomic tests, which are carried out directly on the neoplastic tissue, and modified tissues, but also the dosage of toxic substances (heavy metals, dioxins, furans, PCBs, etc.) analysed “firstly” in the tumour and subsequently in the various biological matrices (tumoral tissues, blood, urine, hair, nails, mother's milk, saliva, etc... skin appendages), as well as specific genetic tests. A key role is also the therapeutic integration in case of the absence of trace elements useful for cellular metabolism, especially for the defence mechanisms, such as Zinc, Copper, Selenium, Magnesium, Cobalt, Iron and Manganese and essential vitamins to improve or modify lack of therapeutic response.

The lack of trace elements could be seen as a possible "predisposition" to lack of response to immunological therapies and, therefore, to a greater risk of aggravation of the disease due to lack of therapeutic response. It is reported in the literature that the lack of Selenium, Zinc, Copper, Magnesium, Manganese, Iron, and Cobalt can be correlated to states of immunodeficiency.

In fact, in several studies, it appears that an absent or reduced therapeutic response of the cancer patient has been related to the lack of activation of specific genes associated with the immune defences, which are not activated. Their non-activation could be referred as low concentrations (or values), especially of Copper and Zinc, but also of Selenium, Cobalt, Manganese, and Iron. For example, Zinc participates, through the Zinc Finger Protein, in the DNA repair processes, and therefore, in the recovery of the immune defences.

Even the altered dosage of these trace elements in different organs and systems finds some correspondences in the possible organ-specific complications, giving us the possibility of predicting in which patients a rapid and aggressive evolution of the disease could arise with an individual-specificity and organ-specificity, but also in which patients a severe or pauci-symptomatic form.

It is important to clarify that the dosage of heavy metals in the tumour and in the various biological matrices does not and cannot be a methodology for preventing neoplastic disease, but a helpful method for improving the therapeutic response of the several therapeutic approaches.

Another parameter to consider is hyperglycaemia in diabetic subjects which, according to various scientific research, is considered a personal risk factor not so much in the formation phase of the neoplastic disease, but in the healing response phase. Recent studies have shown that hyperglycaemia is the cause not only of a delayed and reduced immune response but also of an increase in co-morbidity and mortality. (Updates of the FNOMCeO).

Hyperglycaemia, accompanied by insulin resistance, and consequent hyperinsulinemia, push towards rapid cell proliferation, while the high number of sugars and lipids in the blood act as metabolic fuel for the spread of the tumour. The high insulin-glucose ratio in people with diabetes causes the loss of control of the DNA regulatory genes in some cells, starting a transformation mechanism, as occurs in cancers of the gastrointestinal tract. This brings to a high proliferation, migration, and infiltration of tumour cells that make the disease particularly aggressive.

Following our mutational therapeutic approach, it should be emphasized that even the deficiencies of some substances in diabetic subjects can compromise the extent of the response and modify it. This is the case of Zinc deficiency which could damage the immune response due to reduced production of Zinc Finger Protein.

According to our conclusions, therefore, in the diabetic oncological patient treated with immunotherapy, the therapeutic program must be adjusted with the dosage, both in the tumour and in the various biological matrices, of Zinc and with careful control of the glucose/insulin ratio to avoid a reduced or no response therapeutic.

Once again, environmental pollution has proven to be a severe danger to human health, since many neoplastic diseases have shown a greater incidence, diffusion, aggressiveness, and mortality in the most polluted areas.

This research, still in an early stage, requires considerable resources and more patients, and is meant
to be a further invitation to start a multi-center clinical-scientific program for a broader study of heavy metals, dioxins, PAHs, polychlorinated biphenyls in cancer patients, being treated with immunotherapy, but also for many patients who do not respond to the several standard therapeutic programs. In fact, this program allows to study in these patients, in addition to the genetic mutations, also the presence or deficiency of some substances. Then we pass from the histological model to the model of genetic mutation (mutation) both in the cancer and in the biological matrices, and we can positively affect the therapeutic approach even in cancer patients who do not respond to immunotherapy or who have had a recurrence of the disease after immunotherapy, so as to implement precision and personalized therapeutic programs.

**References**

1. Studio SIMA Relazione circa l’effetto dell’inquinamento.
2. Rapporti ISTISAN 10/22, Ambiente salute, www.iss.it
4. Oltre la verità ufficiale; I danni dell’alluminio. www.disinformazione.it
5. Ministero della Salute, Sezione sicurezza alimentare- CNSA: “Esposizione del consumatore all’alluminio derivante dal contatto alimentare”.
6. CE:STRA.Gestione rifiuti: Quali sono i metalli pesanti? www.cestraecologia.it
7. RIZA.it; Zinco: il minerale che potenzia le difese immunitarie.
9. Ministero della salute; Il Cadmio; www.salute.gov.it
10. Pazienti.it; Avvelenamento da Cadmio.
11. CAIM GROUP; I Metalli inquinanti tossici persistenti; www.caimgroup.it
12. Green Style; Metalli tossici per l’uomo: quali sono; www.greenstyle.it
13. ISSalute, informarsi conoscere scegliere; il Cadmio, www.issalute.it
16. Metalli pesanti e intossicazioni; www.ing.unitn.it
17. I metalli pesanti; www.efsa.europa.eu
18. Intossicazione da metalli pesanti; www.scienzaesalute.silviadedonno.it

21. Sebastiano La Maestra: Dipartimento di Scienze della Salute Università di Genova: Genotossicità dell’aria atmosferica.
24. Flavia Orazzo, Luigi Nespoli, Kazuhiko Ito, etc.: Air Pollution, Aeroallergens, and Emergency Room Visits for Acute Respiratory Disease and Gastroenteric Disorders among Young Children in Six Italian Cities.

- Pasquale Ruffolo, C.M.O. scientific director, former full professor at the National Cancer Institute - Naples, President of ISDE Pompeii.
- Osvaldo Acquaviva, pharmacologist expert in nutraceuticals.
- Pierpaolo Capece, chemist, director of the study of chemical and environmental analysis.
- Bruno Ruffolo, Doctor of Medicine Center.
- Manuela Panunzio, psychologist, expert in psychology of environmental damage.
- Alessandra Paraggio, prevention technician in the environment and in the workplace.
- Andrea Ruffolo, health lawyer.
This page is intentionally left blank
Qualitative Studies on the Factors Influencing the Utilisation of Products Labelled "Food for Special Medicinal Use" (FSMP)

By Chereches Marius Calin, Finta Hajnal, Popa Cristian Olimpiu, Stefanescu Daniela & Muntean Daniela Lucia

Tashkent Pharmaceutical Institute

Abstract- This study aimed to investigate Romanian physicians' awareness, recommendation practices, and opinions regarding using Foods for Special Medical Purposes (FSMPs) products. A total of ten physicians were interviewed using a structured questionnaire, and their responses were analysed using thematic content analysis. The study found that physicians were aware of FSMPs and recommended them to their patients based on nutritional deficits, weight loss, or deglutition impairments. In addition, disease stage, treatment scheme, taste, affordability, and availability were identified as factors influencing the recommendation and use of FSMPs. While physicians generally did not consult clinical trials, clinical experience was deemed essential for recommending FSMPs to patients. Patients' feedback regarding the usage and sourcing of FSMPs was generally positive, with some expressing concerns about the availability of different flavours and the costs of purchasing the products.

Keywords: food for special medical purposes, FSMP, qualitative research, nutritional needs for oncology patients.

GJMR-B Classification: LCC: RM216

Strictly as per the compliance and regulations of:

Global Journal of Medical Research: B Pharma, Drug Discovery, Toxicology & Medicine
Volume 23 Issue 1 Version 1.0 Year 2023
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals
Online ISSN: 2249-4618 & Print ISSN: 0975-5888
Qualitative Studies on the Factors Influencing the Utilisation of Products Labelled "Food for Special Medicinal Use" (FSMP)

Chereches Marius Calin a, Finta Hajnal a, Popa Cristian Olimpiu a, Stefanescu Daniela a* & Muntean Daniela Lucia a

Abstract: This study aimed to investigate Romanian physicians' awareness, recommendation practices, and opinions regarding using Foods for Special Medical Purposes (FSMPs) products. A total of ten physicians were interviewed using a structured questionnaire, and their responses were analysed using thematic content analysis. The study found that physicians were aware of FSMPs and recommended them to their patients based on nutritional deficits, weight loss, or deglutition impairments. In addition, disease stage, treatment scheme, taste, affordability, and availability were identified as factors influencing the recommendation and use of FSMPs. While physicians generally did not consult clinical trials, clinical experience was deemed essential for recommending FSMPs to patients. Patients' feedback regarding the usage and sourcing of FSMPs was generally positive, with some expressing concerns about the availability of different flavours and the costs of purchasing the products. The study concludes that physicians play a vital role in recommending FSMPs to patients and ensuring they have the necessary nutritional support during treatment. However, more patient education materials and collaboration with nutritionists may be required to improve patient outcomes and reduce patient financial burden.

Keywords: food for special medical purposes, FSMP, qualitative research, nutritional needs for oncology patients.

I. Introduction

Food for special medical purposes (FSMPs) are foods designed for people with particular medical disorders and nutritional needs. FSMPs address the dietary requirements of individuals who cannot eat a typical diet because of ailments like malabsorption, metabolic abnormalities, and food allergies. They are often only available with a prescription and are meant to be used under medical supervision.

FSMPs may be used as the sole source of nutrition or as a supplement to a regular diet, depending on the individual's medical needs. These products can come in different forms, such as powders, liquids, or semi-solids and can be used in various settings, including hospitals, long-term care facilities, and home settings.

Inborn errors of metabolism, severe food allergies, and gastrointestinal illnesses like Crohn's disease or ulcerative colitis are a few examples of medical conditions that might call for the usage of FSMPs.

To ensure their effectiveness and safety, FSMPs are governed by regulations and are required to adhere to specific standards. The FSMP industry is regulated by various national and international bodies, such as the European Food Safety Authority (EFSA) and the U.S. Food and Drug Administration (FDA), which set standards for the safety, quality, and efficacy of FSMP products [8, 16, 28, 31].

FSMPs are defined according to Article 2(2)(g) of Regulation 609/2013 as follows:

"food specially processed or formulated and intended for the dietary management of patients, including infants, to be used under medical supervision; it is intended for the exclusive or partial feeding of patients with a limited, impaired or disturbed capacity to take, digest, absorb, metabolise or excrete ordinary food or certain nutrients contained therein, or metabolites, or with other medically-determined nutrient requirements, whose dietary management cannot be achieved by modification of the normal diet alone."

Particularly in Romania, Regulation 128/2018 updated the Regulation 609/2013 mentioned above (named within most of the documents as "FSG Regulation"), and the food notification procedure for special medical purposes (FSMP) was set by Order of the Ministry of Health nr.820/2019[19]. Furthermore, specific standards which apply to FSMP are also outlined within Codex Alimentarius by World Health Organisation [8, 31].

The Commission wanted to clarify the distinctions between FSMP and food supplement products and other ideas relevant to the legislative framework that applies to this category of products through the classification of FSMP, which was subject to specific notice [8].
FSMPs are divided into three groups [8]: (a) nutritionally complete foods with a standard nutrient formulation, (b) nutritionally complete foods with a nutrient-adapted formulation unique to a disease, disorder, or medical condition, and (c) nutritionally incomplete foods with either a standard formulation or a nutrient-adapted formulation unique to a disease, disorder, or medical condition. The first two categories can serve as a patient's only source of nutrition, whereas the third can only increase intake to supplement other sources of nutrients. The FSG Regulation and Codex Alimentarius both clearly define the composition of products, which are defined as FSMP that must contain specific nutrients from the List (vitamins, minerals, amino acids, carnitine-taurine, nucleotides, and coline-inositol) or meet specific requirements (meat food standards, provide scientific support regarding the contribution of ingredients to satisfying nutritional needs and to comply with conditions related to pesticides) [10, 16, 31].

Some writers believe that FSMPs intended for oncology patients may not be adequate for some critical elements such as Zn, Cu, Se, Fe, or Mn, despite the regulatory standards regarding the composition of FSMP implying that the formulations are based on commonly accepted scientific facts [11]. In addition, similar studies indicated sample determination for Se, Zn, K, Mg, and vitamin C differed from (E.U) 2016/128 requirements for enteral tube feed formulae, raising questions about the bioavailability of synthetic vitamins and minerals in comparison to those from natural sources [23].

Products classified as FSMP should be usable by humans and effectively supply nutritional support to the people they are designed for. Other authors put up a different classification that is more workable and acceptable. This classification explains some product categories that fall under the FSMP range and is being developed by an interdisciplinary group of German industry [10, 29].

All regulatory bodies stress the significance of accurately labelling FSMP products, and there are now clear guidelines and explanations. The labelling should provide information regarding energy value, the content of proteins, carbohydrates and fat (per 100 g or ml), the content of vitamins and minerals (per 100 g or ml), osmolarity and/or acid-base balance and the origin and nature of proteins (animal or plants). The manufacturers should disclose the nature of the product, its purpose, and specific usage instructions in sufficient detail. The material shouldn't mislead people or include any characteristics or qualities that imply these items may cure or treat certain illnesses. Additionally, references to usage guidelines should be made, such as use only under medical supervision, information about how to store or retain a container after it has been opened, not suited for parenteral use, etc. It is important to note that while general public advertising should be outlawed, providing educational materials and appropriate resources to healthcare professionals is paramount [8, 9, 31].

Stomatitis and oral mucositis are common in oncology patients receiving chemotherapy or radiation therapy for various types of cancer. These conditions significantly negatively impact the duration, complications, and cost of the entire treatment and the toll they take on the patients' and families' quality of life. Several papers and studies support the value of nutrition and its impact on lowering patient stress and oncology treatment expenses.

Medical costs for patients receiving radiotherapy and developing mucositis or pharyngitis during the treatment are much greater than for those without such conditions, according to a study on patients with head and neck cancer (HNC) and non-small cell lung cancer ($39,313 vs $20,798) [21]. Another study on HNC patients receiving radiotherapy found that 91 percent of patients experienced oral mucositis, and 66 percent of those cases were severe (>Grade 3). Depending on the severity, oral mucositis was associated with increased expenses of $1700–$6000[6]. In addition, the side effects of cancer treatment, such as nausea, vomiting, oral mucositis, and exhaustion, create numerous logistical difficulties and significantly strain the patient and the healthcare system, especially when cancer is treated as a chronic condition [3]. According to a different study, oral or/and G.I. mucositis occurred in 51% of chemotherapy-treated cancer patients with solid tumours or lymphoma. If a patient has oral mucositis or both G.I. and oral mucositis, the projected cost of chemotherapy each cycle is 1.6 times higher and 2.3 times higher, respectively. For patients receiving a hematopoietic cell transplant, an additional point in the peak mucositis score resulted in an additional $25,000 in hospital expenses [17]. In treating several cancers, surgery, chemotherapy (including immunotherapy or target therapy), and radiotherapy may be employed, and the expenditures involved with all these efforts are substantial [13].

Early nutrition support and prevention of oral mucositis or other radiochemotherapy-related side effects for cancer patients determine benefits on all levels (patient, physician, and cost management) by reducing weight loss, fewer radio/chemotherapy breaks, fewer delays in completing radio/chemo cycles, fewer unplanned hospitalisations or shorter lengths of stay in hospitals, and ultimately a higher rate of treatment completion [7, 17, 22, 24].

National healthcare systems reimburse FSMP products in several countries. The E.U. allows for regional or provincial variations in granting FSMP reimbursement. France, Germany, Italy, Spain, and the U.K. are some nations that reimburse FSMPs. Also,
France and Brazil are the countries that have a formal HTA process for medical nutrition [25]. However, the FSMP type and content may affect the reimbursement criteria and procedure. It’s critical to remember that depending on the country and the patient’s medical condition, different restrictions may apply for FSMP product reimbursement ([2, 25, 27]. Chinese researchers and authorities place a high value on FSMP and HTA evaluation for products under this category. Several papers have been written about creating rules, clinical trial prerequisites, and HTA evaluation standards [15, 20, 26].

We examined numerous sources to estimate the size of the worldwide FSMP market, and the results are consistent. The market is estimated to be worth $11.2 billion in 2019 or $13.48 billion in 2021, depending on the source, and it might reach $19.67 billion in 2028 or $19.41 billion in 2030. For the timeframes mentioned above, a CAGR of 5.6 percent to 6.5 percent is anticipated for the growth rate. The key drivers of the growth mentioned by the sourced consulted are the increased awareness of the benefits of this category of products, the increased prevalence of chronic diseases, the increased demand of older adults, the proliferation of new private label manufacturers and the expansion of new distribution channels. More than 65 percent of the market share in the worldwide FSMP market is held by the top 10 companies. Nestle, Danone (Nutricia), Abbott, Bayer, Mead-Johnson, Ajinomoto, Fresenius-Kabi, Lenus Pharma, GFI-Gruppo Farmaimpresa, Galen Limited, BOSSD, and Leskon & EnterNutr are among the companies mentioned. In addition, the 2020 acquisition by Danone of the Murray Goulburn Dairy company in China has indicated a market concentration [5, 18, 30].

An important issue is related to the information regarding the FSMP category. The regulation stipulates that using FSMP needs medical supervision, which is part of this category’s definition. Healthcare professionals give medical supervision, and they can help patients with FSMPs. By healthcare professionals (HCPs), the regulatory body means “persons having qualifications in medicine, nutrition, pharmacy or for other healthcare professionals responsible for maternal care and childcare” according to FSG Regulation, art 9. Without the limits typically imposed on communication to the general public, it is crucial that HCPs may receive complete information regarding the product composition, the clinical justification and supporting data, the appropriate usage, preparation, and the intended target group [2, 10]. However, the legal responsibilities of pharmacies and pharmacists for dispensing FSMPs must be investigated within the current legal framework for the entire pharmacy practice, given that the majority of products in this category are obtained from pharmacies, and there are no formal prescription requirements capable of tracing the recommendation process as a whole [1].

Public outreach efforts should adhere to the aforementioned regulations. Therefore, they are limited to labelling, educational content, and possibly using digital techniques like SEO or SEM. Nevertheless, the digitalisation of healthcare systems is a fact and will significantly impact all future issues. One possible connection between healthcare digitalisation and FSMPs is that digital tools can help monitor, assess, and manage food safety hazards and offer consumers and health professionals information and transparency. Another possible connection is that digital technologies can assist in customising FSMPs based on an individual’s needs, preferences, and circumstances [12].

II. Material and Methods

The research technique examined was in-depth interviews with medical professionals with specialities in the sectors that suggest patients with demands for such products - cancer, ENT, radiation, or surgery - to evaluate the factors influencing the recommendation and use of FSMPs. The in-depth interview method allows the researcher to approach the subject with common questions. It enables us to decide which issues, during a quantitative research phase, the participants should be questioned about. Using this strategy, we can get a wealth of descriptive information on people’s attitudes, behaviours, and perceptions [14].

The following benefits of in-depth interview methods [13] are beneficial for this study:
- Since respondents are dispersed, bringing them all together for a focus group study would be difficult and expensive.
- While a respondent has approximately 10 minutes in a focus group setting, and the other participants may influence his perspective, in an in-depth interview, only 30 to 45 minutes are set aside for the conversation with one respondent.
- The debate may disclose previously assumed habits since the participants fully engage with the topic and tell the whole tale.
- Since using FSMPs requires specialised expertise, the study process necessitates thorough explanations of some subjects.
- Later on, the research agenda incorporates respondents’ viewpoints.

The operators were given instructions on conducting themselves before and during the interview. The logic of the research was emphasised, as well as simple instructions such as the need for a preparatory discussion before the interview, how to conduct the interview itself and to follow the guide as well as how notes should be made and finally, the extraction of answers and the final document for each subject.
The interview's outline contained several subjects for conversation with the issues, including:

- Is the subject recommending any FSMPs? Do they know the category of FSMP?
  How did they become aware of this category?
- Which factors are influencing the subject's recommendation? Clinical proof, the stage of the disease, correlation with the underlying treatment, relationships with other specialties?
- Which particular names or brands are popular or used? What features should the items that the subject recommends or uses have?
- Does the subject know what laws apply to FSMPs? Did the topic have any thoughts on how to make clarity more precise?
- Price: are FSMPs expensive or affordable? Who covers the cost of the products?
- Which are the suppliers and the channels to procure FSMPs products?
- Patients' feedback about the use of FSMPs
- Subject feedback, in their medical capacity
- Few data about the subject of the interview to analyse the answers, such as speciality, type of medical unit in which they work, city and age, experience or associations with academic work.

The operators were equipped additionally with the following:

- Script of introductory talk with the subject about the research, a short description of the research aims and a little information about FSMPs.
- A list of the most popular brands/products available to help the subjects put the questions in context.

Three operators conducted in-depth interviews, and answers from 10 interviews were collected. The interviews were done from October 2022 to January 2023.

We expected doctors to evaluate several considerations before recommending Food for Special Medical Purposes (FSMPs), including:

- The patient's medical condition: FSMPs are designed for those with particular medical conditions with unique dietary requirements. Doctors will assess the patient's condition to decide whether an FSMP is necessary.
- Nutrient requirements: FSMPs are created to satisfy the patient's unique nutrient requirements. Doctors will consider the patient's nutritional demands and determine whether an FSMP can fulfill those needs.
- Digestive capabilities: FSMPs are designed for those whose medical circumstances prevent them from following a typical diet. Doctors will assess the patient's digestibility and decide whether an FSMP is necessary.
- Allergies or intolerances: Patients with severe food allergies or intolerances may take FSMPs. If an FSMP is necessary, doctors will assess the patient's allergies or food intolerances.
- Medical history: The doctor's recommendation of an FSMP may also consider the patient's medical background. For instance, to guarantee enough nutrition, a patient with a history of malabsorption may need an FSMP.
- Accessibility: Doctors will also consider the patient's ability to access the FSMP. This encompasses elements like price, accessibility, and usability.

III. Results and Discussions

Ten in-depth interviews were conducted to gather information, and the distribution of specialities and places of residency is shown in the accompanying table:

<table>
<thead>
<tr>
<th>Residence</th>
<th>Specialities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brasov</td>
<td>ENT's 1</td>
</tr>
<tr>
<td>Cluj Napoca</td>
<td>Oncology 4</td>
</tr>
<tr>
<td>Constanța</td>
<td>Pneumology 1</td>
</tr>
<tr>
<td>București</td>
<td>Radiotherapy 3</td>
</tr>
<tr>
<td>Oradea</td>
<td>Surgeon 1</td>
</tr>
<tr>
<td>Sibiu</td>
<td></td>
</tr>
<tr>
<td>Târgu Mures</td>
<td>2</td>
</tr>
</tbody>
</table>

Key findings were grouped following this article's interview guidelines and narrative logic.

a) Awareness about the FSMPs category of products

All of the subjects interviewed were aware of FSMPs products.

When asked where they first learned about FSMPs, most respondents (7/10) reported they got their information from the producers' medical personnel, and only one said they found out on their own through an internet search. Two respondents stated that they knew these items from their training period for their internship or residency more than ten years prior. The other doctors - their colleagues, who learned from medical reps, were an additional source of information. The statement made by one respondent that information about FSMPs is provided at the medical committee's weekly meetings, where medical representatives attend and present various goods, was also noteworthy. Other respondents addressed the distribution of samples to
patients. The Fresibin, Nutridrink, and Nutricia lines were cited in response to brands.

When we inquired about FSMP information sources, the responses were consistent. They all listed the same kind of resources: medical representatives, inserts and pamphlets ordered by the manufacturers, documents found online through searches, and various manufacturing company presentations at medical congresses and events.

b) How are these products recommended?

The conditions surrounding the recommendation of FSMPs were crucial to our study. Respondents mentioned patients with specific illnesses (pancreatic cancer, gastric cancer, oesophageal cancer, bronchopulmonary cancer, and any cancer of ENT kind) are candidates of choice to benefit from the FSMPs use. Due to the prolonged length of combo treatment, nutritional support with FSMPs is especially necessary for cancer of the ENT type (chemotherapy and radiotherapy). According to one respondent's experience, patients who utilised FSMPs during their treatment likely improved the treatment and had greater success. Several responders mentioned nutritional deficits, weight loss, or deglutition impairments (dysphagia or xerostomia). According to that respondent, one responder further links the usage of FSMPs with the clinic's nutritionist, who suggests such products be used. All respondents mentioned they recommended FSMPs products to their patients. Patients were encouraged to use FSMPs after being discharged from the hospital for those who require such indication.

c) Which factors influence the recommendation?

Usually, the doctor makes the recommendation, and the availability of products in the pharmacies in the neighbourhood of the hospital or patient's residence is considered.

Another respondent was more specific, saying that in ENT cancers, the standard is to recommend FSMPs starting with 2nd week of treatment, which takes six weeks and the patient is monitored every week concerning weight and alimentation.

In addition, it was reported that cancer patients and those with Chronic obstructive pulmonary disease (COPD) had difficulty with deglutition or nutrition and appeared cachectic. Therefore, these products are also advised for their use.

Most respondents mentioned that patients with cancers in ENT, oesophagus, bronchopulmonary or patients with widespread metastasis and palliative needs require FSMPs to keep their nutritional status, weight and general condition satisfactory.

d) Are clinical trials available and influence the recommendations?

Most respondents mentioned they did not consult clinical trials, some justifying due to lack of time. However, some respondents emphasise that clinical experience is essential for recommending FSMP products to patients. At the same time, one respondent considers that there is no significant difference between various brands within this category of products. It is worth mentioning that one respondent considers that clinical trials are available and results are good ones and recommend using such products in line with the stage of the disease. However, the same doctor recommends keeping the patient without medicinal products and with ordinary alimentation as long as possible.

e) Does the disease stage influence the choice of the FSMPs?

Respondents generally indicated weight loss and body mass index (BMI) as principal triggers for recommending FSMP to patients under treatment. The primary need is to have the patient well balanced from the nutritional point of view to support chemo or radiotherapy treatment for the whole duration. FSMP products are helping patients to achieve this objective. The appearance of problems with deglutition or food absorption also triggered the recommendation of using these products, as well as certain medical conditions (such as gastrectomy, oesophagectomy, acute pancreatitis or complete dysphagia for solid food).

A subject stressed that, when making a suggestion, the affordability must be addressed alongside medical reasons.

f) Is the recommendation correlated with the treatment scheme?

FSMPs are recommended for cancers like colon cancer or pancreatic cancer with the condition that makes ordinary alimentation challenging to achieve, according to one respondent or the recommendation being linked with BMI or weight loss.

Another respondent considers that the administration has nothing to do with the treatment scheme, but with the comfort or the patient's needs, so the FSMPs might be recommendable to those in need.

The linkage with the treatment is that doctors must ensure that the patient can follow the treatment scheme. Particularly in radiotherapy, postponing or delaying treatment is not an option. Thus FSMP products may help the patient to cope with the side effects of chemo or radiotherapy and enable him to keep up with and complete the whole treatment scheme successfully.
g) Which products or brands are used or recommended?
The respondents spontaneously mentioned four brands, as per the following table:

<table>
<thead>
<tr>
<th>Brand</th>
<th>Mentions, out of total</th>
</tr>
</thead>
<tbody>
<tr>
<td>MediDrink</td>
<td>1/10</td>
</tr>
<tr>
<td>Nutridrink</td>
<td>3/10</td>
</tr>
<tr>
<td>Fresubin</td>
<td>9/10</td>
</tr>
<tr>
<td>Nutricia</td>
<td>1/10</td>
</tr>
</tbody>
</table>

In addition to brand names, several respondents cited other requirements for items to be utilised, including hypercaloric or normocaloric content, high protein content, and various tastes and flavours.

h) What features and characteristics of products make them useful?
The taste and flavour are the most significant and commonly cited characteristics. According to the feedback received by the physicians in our panel, some patients claimed that certain products were overly sweet or had a high level of acidity. In contrast, others disapproved of the products that tasted like bananas. Conversely, patients more readily accepted FSMPs when they tasted strawberries and chocolate.

One respondent gave a more detailed description, emphasising the demand for lactose-free, gluten-free products, high in vitamins, minerals, and proteins and hypercaloric.

i) Is the pertinent legal framework known? Are there any necessary changes that need to be made?
With one exception, our respondents were unaware if there is in place specific legislation governing FSMPs and how this product category differs from food supplements. One participant had in-depth knowledge of E.U. regulations, informational requirements, informational requirements for the public and specialists, classification, quality standards, labelling, indication, and precautions. No change to the current legislation was mentioned as necessary, identified or proposed by participants in this research.

j) Price and affordability
Participants paid careful attention to the concerns regarding the pricing and accessibility of FSMPs, which were identified as an important topic affecting the use and availability of FSMPs for in-need patients.

Three respondents indicated their awareness of prices; one accurately identified the average bottle price as 15 RON, but the other two knew a price range of 30–50 RON. One even brought up the substantial distinction between Nutridrink, an example of a more reasonably priced product with 30 RON/bottle, and Fresubin, an example of an expensive product with 50 RON/bottle. According to respondents’ calculations, a patient would require products costing between 30 and 50 RON for every bottle (4-5,000 RON or 800-1,000 Euro), which is out of reach for many patients, given the overall cost of cancer therapy.

We gathered some pricing for products in this category from online pharmacies or wholesalers and their spot prices to explain the mathematics of the price problem. The following table displays the findings.

<table>
<thead>
<tr>
<th>Product</th>
<th>List price per pack</th>
<th>Source of information</th>
<th>bottles per pack</th>
<th>price per bottle</th>
<th>price per 7 weeks treatment (2 bottles/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresubin Protein Energy,</td>
<td>62.88 RON</td>
<td><a href="https://alimentespeciale.ro/fresubin-protein-energy-drink-fructe-tropicale-x-200ml-">https://alimentespeciale.ro/fresubin-protein-energy-drink-fructe-tropicale-x-200ml-</a></td>
<td>4</td>
<td>15.72 RON</td>
<td>1,540.53 RON</td>
</tr>
<tr>
<td>4x200ml</td>
<td></td>
<td>fresenius-kabi/103593.htm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bautura cu aroma de vanilie</td>
<td>80.02 RON</td>
<td><a href="https://alimentespeciale.ro/fresubin-2kcal-drink-x-200ml-vanilie-fresenius-kabi/100992">https://alimentespeciale.ro/fresubin-2kcal-drink-x-200ml-vanilie-fresenius-kabi/100992</a></td>
<td>4</td>
<td>20.01 RON</td>
<td>1,960.49 RON</td>
</tr>
<tr>
<td>Fresubin Pro Drink Alune de</td>
<td>120.33 RON</td>
<td><a href="https://alimentespeciale.ro/fresubin-pro-drink-alune-de-padure-4x200ml-fresenius-">https://alimentespeciale.ro/fresubin-pro-drink-alune-de-padure-4x200ml-fresenius-</a></td>
<td>4</td>
<td>30.08 RON</td>
<td>2,948.09 RON</td>
</tr>
<tr>
<td>padure 4x200ml - hypercaloric,</td>
<td></td>
<td>kabi/161630.htm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hyper-proteic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Frelinbin, 4x200 ml, Fresenius Kabi Germania 57.50 RON https://comenzi.farmaciatei.ro/vitamine-si-suplimente/digestie/nutritie-speciala/bautura-energizanta-cu-proteine-aroma-de-vanilie-fresubin-4x200-ml-fresenius-kabi-germania-p323667 4 14.38 RON 1,408.75 RON

MediDrink plus vanilie x200ml 17.00 RON https://www.farmaciilenapofarm.ro/nutritie-speciala/medidrink-plus-vanilie-x200ml-39202.html 1 17.00 RON 1,666.00 RON

Nutridrink banane x 200ml Nutricia 14.62 RON https://alimentespeciale.ro/nutridrink-banane-x-200ml-nutricia/103021.html 1 14.62 RON 1,432.76 RON

Sources for prices have been accessed on March 2, 2023

Using the price data from the above sources, the cost for a patient using two bottles daily for seven weeks would range from 1,433 to 2,948 RON (i.e. 290-590 Euro). Furthermore, the National Institute of Statistics, cited by Statista, said that the average salary in Romania was 3,416 RON in 2021, which is necessary to make the previous information pertinent.

The responses from the other respondents were less detailed. At the same time, 1/3 of them said that these products are generally accessible and affordable, and the other third claimed that they are far too expensive for patients to afford to be used as they should be.

k) Who is paying for FSMPs products?

In Romania, FSMPs are not reimbursed; consequently, the patient, their family, or the hospital covers the expense of these items during hospitalisation. At the same time, most treatments are also administered in an outpatient setting, and most respondents to our survey said that the patient is responsible for purchasing these goods. There were two mentions of the hospital purchasing such products for hospitalised patients, out of the general budget of the healthcare unit, or it received donations. Respondents also emphasised that for some patients, the cost of purchasing the required quantity of FSMPs products may exceed their financial means.

l) How do patients source FSMP products?

As far as our respondents learned from personal experience, buying these products from pharmacies, online pharmacies, or online shops doesn't present any significant problems. However, some stressed the necessity of placing a preorder to guarantee that the required versions will be available. One participant spoke about successfully obtaining Medidrink from the online pharmacy Spring Farma and buying FSMP products online rather than from traditional pharmacies or the neighbour country, ungary, which may be more affordable in some cases. Pharmacy, online shopping, and charity donations were the supply methods highlighted. One participant brought up a hospital-organised tender for the purchase of Fresubin.

Additionally, we examined the market data from the research firm Cegedim [4], which compiles data from hospitals and retail pharmacies in Romania, as shown in the following table.

Table IV: Sales (units and value) for FSMP on pharmacy channel in Romania for the year 2022 (source: Cegedim)

<table>
<thead>
<tr>
<th>MANUFACTURER</th>
<th>PRODUCT NAME</th>
<th>Sales 2022 (units)</th>
<th>Value 2022 (PPP, RON)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRESENIUS-KABI</td>
<td>FRESUBIN</td>
<td>106,178</td>
<td>4,807,822</td>
</tr>
<tr>
<td></td>
<td>DIBEN</td>
<td>92,786</td>
<td>4,032,172</td>
</tr>
<tr>
<td></td>
<td>SUPPORTAN</td>
<td>4,692</td>
<td>203,146</td>
</tr>
<tr>
<td></td>
<td>SURVIMED</td>
<td>4,220</td>
<td>279,809</td>
</tr>
<tr>
<td></td>
<td>PROVIDEXTRA DRINK</td>
<td>2,722</td>
<td>165,364</td>
</tr>
<tr>
<td></td>
<td>CALSHAKE</td>
<td>663</td>
<td>44,565</td>
</tr>
<tr>
<td></td>
<td>FREBINI</td>
<td>502</td>
<td>19,499</td>
</tr>
<tr>
<td></td>
<td>KABI GLUTAMINE</td>
<td>453</td>
<td>18,469</td>
</tr>
<tr>
<td>NESTLE</td>
<td>NESTLE OPTIMUM</td>
<td>140</td>
<td>44,798</td>
</tr>
<tr>
<td></td>
<td>MODULEN</td>
<td>2,1532</td>
<td>790,416</td>
</tr>
<tr>
<td></td>
<td>OPTIFIBRE</td>
<td>20,971</td>
<td>749,973</td>
</tr>
<tr>
<td></td>
<td>NUTREN OPTIMUM</td>
<td>420</td>
<td>20,571</td>
</tr>
<tr>
<td></td>
<td>NUTRICIA</td>
<td>141</td>
<td>19,872</td>
</tr>
<tr>
<td></td>
<td>NUTRIDRINK</td>
<td>2,408</td>
<td>25,558</td>
</tr>
</tbody>
</table>

© 2023 Global Journals
For 2022, we identified reports of relatively low sales and only a few brands. Although this is the only source we could find, it is improbable that only 106,178 units were sold through retail pharmacies in Romania. We can only speculate that online pharmacies are not counted and that most online shops did not report sales to Cegedim, thus underestimating the totals. Only Fresubin indicates large sales among the important manufacturers, who are present on the market with more brands than respondents to our research reported (over 90 percent of the total).

m) What feedback did the responders receive from their patients?

We can group the feedback on two main aspects – how patients use the products and how they can source them.

Patients are generally happy with the products. However, patients are concerned about the availability of different flavours to suit specific needs in terms of usage, especially in the case of some patients whose tastes are altered during chemotherapy or radiotherapy. In addition, it is important to note that certain patients have expressed concerns about items being either too sweet or acidic in some circumstances.

Regarding sourcing, some patients expressed the necessity to place an order in advance, ask family members for information, or look up sources online. However, the biggest problem mentioned is that most patients need help to secure the funding necessary to buy the supplements during their therapy, especially in cases of a 6-7 weeks treatment scheme associated with the condition requiring FSMPs aid.

n) The opinion of the physicians regarding FSMPs

The most important objective for the participants in this research concerning the use of FSMP products is to help patients to go through the course of treatment in an acceptable physical shape, and nutritional status is paramount for such an aim. For example, one participant in the study reported that FSMP users were less likely to have stomatitis or mucositis. In addition, most survey respondents said that patients were better equipped nutritionally to withstand the effects of chemotherapy and/or radiotherapy over their whole course.

Since some patients cannot drink coffee during therapy, suggestions such as adding a coffee-like flavour were made. Since the financial burden currently exists for cancer patients, the added expense of FSMP products causes enormous obstacles for patients. Hence respondents to our poll emphasised the necessity for a method to pay these costs externally through reimbursement or a similar mechanism.

Doctors emphasise that these expenses (i.e. for FSMPs) are less than what would be needed for chemotherapy or radiation therapy. Since this keeps the patients well enough to complete the course successfully, the treatments are unquestionably worthwhile.

o) Extra details provided by respondents

We asked respondents about any specific subjects they would like to bring up after the interview, and the following we believe merits discussion:

− Using FSMP would lower the cost of patient care while being necessary for finishing the treatment.
− It might be beneficial to commission more patient education materials on FSMP.
− The help and collaboration of a nutritionist are critical since they free up the doctor from this responsibility and assist patients at risk.
− In some extreme cases (i.e. N.G. tube feeding), using FSMPs would lower the burden on the budget necessary for treatment and the patient's comfort.

IV. Conclusions

The study’s findings provide insight into Romanian physicians’ awareness, recommendation practices, and opinions regarding the use of FSMPs. Physicians recommend FSMPs to patients based on specific medical conditions, treatment schemes, taste preferences, and affordability. Disease stage and treatment scheme were identified as factors that influence the recommendation and use of FSMPs. Clinical experience was deemed essential for recommending FSMPs to patients, while patients’ feedback regarding the usage and sourcing of FSMPs was generally positive. The study concludes that physicians play a crucial role in ensuring that patients have the necessary nutritional support during treatment. However, more patient education materials and collaboration with nutritionists may be required to improve patient outcomes and reduce patient financial burden. Overall, the study highlights the importance of FSMPs in patient care and the need for further research and collaboration between healthcare professionals to optimise the use of these products.

Acknowledgements

This research was carried out with the support of the University of Medicine, Pharmacy, Science and technology “George Emil Palade” of Tirgu Mures Romania and the financial support of the Pharm Connect Services SRL through the research grant contract 8303/6.12.2021.

References Références Referencias

2. Bushell C, Ruthsatz M. Revising the EU FSMP Regulatory Framework: Laying a Foundation for

© 2023 Global Journals
4. Cegedim. Pharma & Hospital. 2022
29. Stippler D, Bode V, Fischer M, Kollex K, Rohde E, et al. Proposal for a new practicable categorization...


**MEMBERSHIPS**

**FELLOWS/ASSOCIATES OF MEDICAL RESEARCH COUNCIL**

**FMRC/AMRC MEMBERSHIPS**

**INTRODUCTION**

FMRC/AMRC is the most prestigious membership of Global Journals accredited by Open Association of Research Society, U.S.A (OARS). The credentials of Fellow and Associate designations signify that the researcher has gained the knowledge of the fundamental and high-level concepts, and is a subject matter expert, proficient in an expertise course covering the professional code of conduct, and follows recognized standards of practice. The credentials are designated only to the researchers, scientists, and professionals that have been selected by a rigorous process by our Editorial Board and Management Board.

Associates of FMRC/AMRC are scientists and researchers from around the world are working on projects/researches that have huge potentials. Members support Global Journals’ mission to advance technology for humanity and the profession.

**FMRC**

**FELLOW OF MEDICAL RESEARCH COUNCIL**

FELLOW OF MEDICAL RESEARCH COUNCIL is the most prestigious membership of Global Journals. It is an award and membership granted to individuals that the Open Association of Research Society judges to have made a 'substantial contribution to the improvement of computer science, technology, and electronics engineering.

The primary objective is to recognize the leaders in research and scientific fields of the current era with a global perspective and to create a channel between them and other researchers for better exposure and knowledge sharing. Members are most eminent scientists, engineers, and technologists from all across the world. Fellows are elected for life through a peer review process on the basis of excellence in the respective domain. There is no limit on the number of new nominations made in any year. Each year, the Open Association of Research Society elect up to 12 new Fellow Members.
Benefit

To the Institution

Get Letter of Appreciation

Global Journals sends a letter of appreciation of author to the Dean or CEO of the University or Company of which author is a part, signed by editor in chief or chief author.

Exclusive Network

Get Access to a Closed Network

A FMRC member gets access to a closed network of Tier 1 researchers and scientists with direct communication channel through our website. Fellows can reach out to other members or researchers directly. They should also be open to reaching out by other.

Certificate

Certificate, LoR and Laser-Momento

Fellows receive a printed copy of a certificate signed by our Chief Author that may be used for academic purposes and a personal recommendation letter to the dean of member's university.

Designation

Get Honored Title of Membership

Fellows can use the honored title of membership. The “FMRC” is an honored title which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., FMRC or William Walldroff, M.S., FMRC.

Recognition on the Platform

Better Visibility and Citation

All the Fellow members of FMRC get a badge of “Leading Member of Global Journals” on the Research Community that distinguishes them from others. Additionally, the profile is also partially maintained by our team for better visibility and citation. All fellows get a dedicated page on the website with their biography.
**FUTURE WORK**

**GET DISCOUNTS ON THE FUTURE PUBLICATIONS**
Fellows receive discounts on the future publications with Global Journals up to 60%. Through our recommendation programs, members also receive discounts on publications made with OARS affiliated organizations.

**GJ INTERNAL ACCOUNT**

**UNLIMITED FORWARD OF EMAILS**
Fellows get secure and fast GJ work emails with unlimited storage of emails that they may use them as their primary email. For example, john [AT] globaljournals [DOT] org.

**PREMIUM TOOLS**

**ACCESS TO ALL THE PREMIUM TOOLS**
To take future researches to the zenith, fellows receive access to all the premium tools that Global Journals have to offer along with the partnership with some of the best marketing leading tools out there.

**CONFERENCES & EVENTS**

**ORGANIZE SEMINAR/CONFERENCE**
Fellows are authorized to organize symposium/seminar/conference on behalf of Global Journal Incorporation (USA). They can also participate in the same organized by another institution as representative of Global Journal. In both the cases, it is mandatory for him to discuss with us and obtain our consent. Additionally, they get free research conferences (and others) alerts.

**EARLY INVITATIONS**

**EARLY INVITATIONS TO ALL THE SYMPOSIUMS, SEMINARS, CONFERENCES**
All fellows receive the early invitations to all the symposiums, seminars, conferences and webinars hosted by Global Journals in their subject.
PUBLISHING ARTICLES & BOOKS

EARN 60% OF SALES PROCEEDS
Fellows can publish articles (limited) without any fees. Also, they can earn up to 70% of sales proceeds from the sale of reference/review books/literature/publishing of research paper. The FMRC member can decide its price and we can help in making the right decision.

REVIEWERS

GET A REMUNERATION OF 15% OF AUTHOR FEES
Fellow members are eligible to join as a paid peer reviewer at Global Journals Incorporation (USA) and can get a remuneration of 15% of author fees, taken from the author of a respective paper.

ACCESS TO EDITORIAL BOARD

BECOME A MEMBER OF THE EDITORIAL BOARD
Fellows and Associates may join as a member of the Editorial Board of Global Journals Incorporation (USA) after successful completion of three years as Fellow and as Peer Reviewer.

AND MUCH MORE

GET ACCESS TO SCIENTIFIC MUSEUMS AND OBSERVATORIES ACROSS THE GLOBE
All members get access to 5 selected scientific museums and observatories across the globe. All researches published with Global Journals will be kept under deep archival facilities across regions for future protections and disaster recovery. They get 10 GB free secure cloud access for storing research files.
ASSOCIATE OF MEDICAL RESEARCH COUNCIL

ASSOCIATE OF MEDICAL RESEARCH COUNCIL is the membership of Global Journals awarded to individuals that the Open Association of Research Society judges to have made a 'substantial contribution to the improvement of computer science, technology, and electronics engineering. The primary objective is to recognize the leaders in research and scientific fields of the current era with a global perspective and to create a channel between them and other researchers for better exposure and knowledge sharing. Members are most eminent scientists, engineers, and technologists from all across the world. Associate membership can later be promoted to Fellow Membership. Associates are elected for life through a peer review process on the basis of excellence in the respective domain. There is no limit on the number of new nominations made in any year. Each year, the Open Association of Research Society elect up to 12 new Associate Members.
**Benefit**

**To the Institution**

**Get Letter of Appreciation**
Global Journals sends a letter of appreciation of author to the Dean or CEO of the University or Company of which author is a part, signed by editor in chief or chief author.

**Exclusive Network**

**Get Access to a Closed Network**
A AMRC member gets access to a closed network of Tier 2 researchers and scientists with direct communication channel through our website. Associates can reach out to other members or researchers directly. They should also be open to reaching out by other.

**Certificate**

**Certificate, LoR and Laser-Momento**
Associates receive a printed copy of a certificate signed by our Chief Author that may be used for academic purposes and a personal recommendation letter to the dean of member’s university.

**Designation**

**Get Honored Title of Membership**
Associates can use the honored title of membership. The “AMRC” is an honored title which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., AMRC or William Walldroff, M.S., AMRC.

**Recognition on the Platform**

**Better Visibility and Citation**
All the Associate members of AMRC get a badge of "Leading Member of Global Journals" on the Research Community that distinguishes them from others. Additionally, the profile is also partially maintained by our team for better visibility and citation.

© Copyright by Global Journals | Guidelines Handbook
FUTURE WORK
GET DISCOUNTS ON THE FUTURE PUBLICATIONS
Associates receive discounts on future publications with Global Journals up to 30%. Through our recommendation programs, members also receive discounts on publications made with OARS affiliated organizations.

GJ ACCOUNT
UNLIMITED FORWARD OF EMAILS
Associates get secure and fast GJ work emails with 5GB forward of emails that they may use them as their primary email. For example, john[AT]globaljournals[DOT]org.

PREMIUM TOOLS
ACCESS TO ALL THE PREMIUM TOOLS
To take future researches to the zenith, fellows receive access to almost all the premium tools that Global Journals have to offer along with the partnership with some of the best marketing leading tools out there.

CONFERENCES & EVENTS
ORGANIZE SEMINAR/CONFERENCE
Associates are authorized to organize symposium/seminar/conference on behalf of Global Journal Incorporation (USA). They can also participate in the same organized by another institution as representative of Global Journal. In both the cases, it is mandatory for him to discuss with us and obtain our consent. Additionally, they get free research conferences (and others) alerts.

EARLY INVITATIONS
EARLY INVITATIONS TO ALL THE SYMPOSIUMS, SEMINARS, CONFERENCES
All associates receive the early invitations to all the symposiums, seminars, conferences and webinars hosted by Global Journals in their subject.
**PUBLISHING ARTICLES & BOOKS**

**EARN 60% OF SALES PROCEEDS**

Associates can publish articles (limited) without any fees. Also, they can earn up to 30-40% of sales proceeds from the sale of reference/review books/literature/publishing of research paper.

**REVIEWSERS**

**GET A REMUNERATION OF 15% OF AUTHOR FEES**

Associate members are eligible to join as a paid peer reviewer at Global Journals Incorporation (USA) and can get a remuneration of 15% of author fees, taken from the author of a respective paper.

**AND MUCH MORE**

**GET ACCESS TO SCIENTIFIC MUSEUMS AND OBSERVATORIES ACROSS THE GLOBE**

All members get access to 2 selected scientific museums and observatories across the globe. All researches published with Global Journals will be kept under deep archival facilities across regions for future protections and disaster recovery. They get 5 GB free secure cloud access for storing research files.
<table>
<thead>
<tr>
<th><strong>ASSOCIATE</strong></th>
<th><strong>FELLOW</strong></th>
<th><strong>RESEARCH GROUP</strong></th>
<th><strong>BASIC</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>$4800</td>
<td>$6800</td>
<td>$12500.00</td>
<td>APC per article</td>
</tr>
<tr>
<td>lifetime designation</td>
<td>lifetime designation</td>
<td>organizational</td>
<td></td>
</tr>
<tr>
<td><strong>Certificate</strong>, LoR and Momento</td>
<td><strong>Certificate</strong>, LoR and Momento</td>
<td><strong>Certificates</strong>, LoRs and Momentos</td>
<td></td>
</tr>
<tr>
<td>2 discounted publishing/year</td>
<td>Unlimited discounted publishing/year</td>
<td>Unlimited free publishing/year</td>
<td></td>
</tr>
<tr>
<td><strong>Gradation</strong> of Research</td>
<td><strong>Gradation</strong> of Research</td>
<td><strong>Gradation</strong> of Research</td>
<td></td>
</tr>
<tr>
<td>10 research contacts/day</td>
<td>Unlimited research contacts/day</td>
<td>Unlimited research contacts/day</td>
<td></td>
</tr>
<tr>
<td>1 GB Cloud Storage</td>
<td>5 GB Cloud Storage</td>
<td>Unlimited Cloud Storage</td>
<td></td>
</tr>
<tr>
<td><strong>GJ Community Access</strong></td>
<td><strong>GJ Community Access</strong></td>
<td><strong>GJ Community Access</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Online Presence</strong> Assistance</td>
<td><strong>Online Presence</strong> Assistance</td>
<td><strong>Online Presence</strong> Assistance</td>
<td></td>
</tr>
<tr>
<td><strong>GJ Community Access</strong></td>
<td><strong>GJ Community Access</strong></td>
<td><strong>GJ Community Access</strong></td>
<td></td>
</tr>
</tbody>
</table>
**Preferred Author Guidelines**

We accept the manuscript submissions in any standard (generic) format.

We typeset manuscripts using advanced typesetting tools like Adobe In Design, CorelDraw, TeXnicCenter, and TeXStudio. We usually recommend authors submit their research using any standard format they are comfortable with, and let Global Journals do the rest.

Alternatively, you can download our basic template from https://globaljournals.org/Template

Authors should submit their complete paper/article, including text illustrations, graphics, conclusions, artwork, and tables. Authors who are not able to submit manuscript using the form above can email the manuscript department at submit@globaljournals.org or get in touch with chiefeditor@globaljournals.org if they wish to send the abstract before submission.

**Before and during Submission**

Authors must ensure the information provided during the submission of a paper is authentic. Please go through the following checklist before submitting:

1. Authors must go through the complete author guideline and understand and agree to Global Journals' ethics and code of conduct, along with author responsibilities.
2. Authors must accept the privacy policy, terms, and conditions of Global Journals.
3. Ensure corresponding author’s email address and postal address are accurate and reachable.
4. Manuscript to be submitted must include keywords, an abstract, a paper title, co-author(s’) names and details (email address, name, phone number, and institution), figures and illustrations in vector format including appropriate captions, tables, including titles and footnotes, a conclusion, results, acknowledgments and references.
5. Authors should submit paper in a ZIP archive if any supplementary files are required along with the paper.
6. Proper permissions must be acquired for the use of any copyrighted material.
7. Manuscript submitted must not have been submitted or published elsewhere and all authors must be aware of the submission.

**Declaration of Conflicts of Interest**

It is required for authors to declare all financial, institutional, and personal relationships with other individuals and organizations that could influence (bias) their research.

**Policy on Plagiarism**

Plagiarism is not acceptable in Global Journals submissions at all.

Plagiarized content will not be considered for publication. We reserve the right to inform authors’ institutions about plagiarism detected either before or after publication. If plagiarism is identified, we will follow COPE guidelines:

Authors are solely responsible for all the plagiarism that is found. The author must not fabricate, falsify or plagiarize existing research data. The following, if copied, will be considered plagiarism:

- Words (language)
- Ideas
- Findings
- Writings
- Diagrams
- Graphs
- Illustrations
- Lectures

© Copyright by Global Journals | Guidelines Handbook
Authorship Policies

Global Journals follows the definition of authorship set up by the Open Association of Research Society, USA. According to its guidelines, authorship criteria must be based on:

1. Substantial contributions to the conception and acquisition of data, analysis, and interpretation of findings.
2. Drafting the paper and revising it critically regarding important academic content.
3. Final approval of the version of the paper to be published.

Changes in Authorship

The corresponding author should mention the name and complete details of all co-authors during submission and in manuscript. We support addition, rearrangement, manipulation, and deletions in authors list till the early view publication of the journal. We expect that corresponding author will notify all co-authors of submission. We follow COPE guidelines for changes in authorship.

Copyright

During submission of the manuscript, the author is confirming an exclusive license agreement with Global Journals which gives Global Journals the authority to reproduce, reuse, and republish authors’ research. We also believe in flexible copyright terms where copyright may remain with authors/employers/institutions as well. Contact your editor after acceptance to choose your copyright policy. You may follow this form for copyright transfers.

Appealing Decisions

Unless specified in the notification, the Editorial Board’s decision on publication of the paper is final and cannot be appealed before making the major change in the manuscript.

Acknowledgments

Contributors to the research other than authors credited should be mentioned in Acknowledgments. The source of funding for the research can be included. Suppliers of resources may be mentioned along with their addresses.

Declaration of funding sources

Global Journals is in partnership with various universities, laboratories, and other institutions worldwide in the research domain. Authors are requested to disclose their source of funding during every stage of their research, such as making analysis, performing laboratory operations, computing data, and using institutional resources, from writing an article to its submission. This will also help authors to get reimbursements by requesting an open access publication letter from Global Journals and submitting to the respective funding source.

Preparing your Manuscript

Authors can submit papers and articles in an acceptable file format: MS Word (doc, docx), LaTeX (.tex, .zip or .rar including all of your files), Adobe PDF (.pdf), rich text format (.rtf), simple text document (.txt), Open Document Text (.odt), and Apple Pages (.pages). Our professional layout editors will format the entire paper according to our official guidelines. This is one of the highlights of publishing with Global Journals—authors should not be concerned about the formatting of their paper. Global Journals accepts articles and manuscripts in every major language, be it Spanish, Chinese, Japanese, Portuguese, Russian, French, German, Dutch, Italian, Greek, or any other national language, but the title, subtitle, and abstract should be in English. This will facilitate indexing and the pre-peer review process.

The following is the official style and template developed for publication of a research paper. Authors are not required to follow this style during the submission of the paper. It is just for reference purposes.

© Copyright by Global Journals | Guidelines Handbook
Manuscript Style Instruction (Optional)

- Microsoft Word Document Setting Instructions.
- Font type of all text should be Swis721 Lt BT.
- Page size: 8.27” x 11””, left margin: 0.65, right margin: 0.65, bottom margin: 0.75.
- Paper title should be in one column of font size 24.
- Author name in font size of 11 in one column.
- Abstract: font size 9 with the word “Abstract” in bold italics.
- Main text: font size 10 with two justified columns.
- Two columns with equal column width of 3.38 and spacing of 0.2.
- First character must be three lines drop-capped.
- The paragraph before spacing of 1 pt and after of 0 pt.
- Line spacing of 1 pt.
- Large images must be in one column.
- The names of first main headings (Heading 1) must be in Roman font, capital letters, and font size of 10.
- The names of second main headings (Heading 2) must not include numbers and must be in italics with a font size of 10.

Structure and Format of Manuscript

The recommended size of an original research paper is under 15,000 words and review papers under 7,000 words. Research articles should be less than 10,000 words. Research papers are usually longer than review papers. Review papers are reports of significant research (typically less than 7,000 words, including tables, figures, and references)

A research paper must include:

a) A title which should be relevant to the theme of the paper.

b) A summary, known as an abstract (less than 150 words), containing the major results and conclusions.

c) Up to 10 keywords that precisely identify the paper’s subject, purpose, and focus.

d) An introduction, giving fundamental background objectives.

e) Resources and techniques with sufficient complete experimental details (wherever possible by reference) to permit repetition, sources of information must be given, and numerical methods must be specified by reference.

f) Results which should be presented concisely by well-designed tables and figures.

g) Suitable statistical data should also be given.

h) All data must have been gathered with attention to numerical detail in the planning stage.

Design has been recognized to be essential to experiments for a considerable time, and the editor has decided that any paper that appears not to have adequate numerical treatments of the data will be returned unrefereed.

i) Discussion should cover implications and consequences and not just recapitulate the results; conclusions should also be summarized.

j) There should be brief acknowledgments.

k) There ought to be references in the conventional format. Global Journals recommends APA format.

Authors should carefully consider the preparation of papers to ensure that they communicate effectively. Papers are much more likely to be accepted if they are carefully designed and laid out, contain few or no errors, are summarizing, and follow instructions. They will also be published with much fewer delays than those that require much technical and editorial correction.

The Editorial Board reserves the right to make literary corrections and suggestions to improve brevity.
It is necessary that authors take care in submitting a manuscript that is written in simple language and adheres to published guidelines.

All manuscripts submitted to Global Journals should include:

**Title**

The title page must carry an informative title that reflects the content, a running title (less than 45 characters together with spaces), names of the authors and co-authors, and the place(s) where the work was carried out.

**Author details**

The full postal address of any related author(s) must be specified.

**Abstract**

The abstract is the foundation of the research paper. It should be clear and concise and must contain the objective of the paper and inferences drawn. It is advised to not include big mathematical equations or complicated jargon.

Many researchers searching for information online will use search engines such as Google, Yahoo or others. By optimizing your paper for search engines, you will amplify the chance of someone finding it. In turn, this will make it more likely to be viewed and cited in further works. Global Journals has compiled these guidelines to facilitate you to maximize the web-friendliness of the most public part of your paper.

**Keywords**

A major lynchpin of research work for the writing of research papers is the keyword search, which one will employ to find both library and internet resources. Up to eleven keywords or very brief phrases have to be given to help data retrieval, mining, and indexing.

One must be persistent and creative in using keywords. An effective keyword search requires a strategy: planning of a list of possible keywords and phrases to try.

Choice of the main keywords is the first tool of writing a research paper. Research paper writing is an art. Keyword search should be as strategic as possible.

One should start brainstorming lists of potential keywords before even beginning searching. Think about the most important concepts related to research work. Ask, “What words would a source have to include to be truly valuable in a research paper?” Then consider synonyms for the important words.

It may take the discovery of only one important paper to steer in the right keyword direction because, in most databases, the keywords under which a research paper is abstracted are listed with the paper.

**Numerical Methods**

Numerical methods used should be transparent and, where appropriate, supported by references.

**Abbreviations**

Authors must list all the abbreviations used in the paper at the end of the paper or in a separate table before using them.

**Formulas and equations**

Authors are advised to submit any mathematical equation using either MathJax, KaTeX, or LaTeX, or in a very high-quality image.

**Tables, Figures, and Figure Legends**

Tables: Tables should be cautiously designed, uncrowned, and include only essential data. Each must have an Arabic number, e.g., Table 4, a self-explanatory caption, and be on a separate sheet. Authors must submit tables in an editable format and not as images. References to these tables (if any) must be mentioned accurately.
Figures

Figures are supposed to be submitted as separate files. Always include a citation in the text for each figure using Arabic numbers, e.g., Fig. 4. Artwork must be submitted online in vector electronic form or by emailing it.

Preparation of Electronic Figures for Publication

Although low-quality images are sufficient for review purposes, print publication requires high-quality images to prevent the final product being blurred or fuzzy. Submit (possibly by e-mail) EPS (line art) or TIFF (halftone/photographs) files only. MS PowerPoint and Word Graphics are unsuitable for printed pictures. Avoid using pixel-oriented software. Scans (TIFF only) should have a resolution of at least 350 dpi (halftone) or 700 to 1100 dpi (line drawings). Please give the data for figures in black and white or submit a Color Work Agreement form. EPS files must be saved with fonts embedded (and with a TIFF preview, if possible).

For scanned images, the scanning resolution at final image size ought to be as follows to ensure good reproduction: line art: >650 dpi; halftones (including gel photographs): >350 dpi; figures containing both halftone and line images: >650 dpi.

Color charges: Authors are advised to pay the full cost for the reproduction of their color artwork. Hence, please note that if there is color artwork in your manuscript when it is accepted for publication, we would require you to complete and return a Color Work Agreement form before your paper can be published. Also, you can email your editor to remove the color fee after acceptance of the paper.

Tips for Writing a Good Quality Medical Research Paper

1. Choosing the topic: In most cases, the topic is selected by the interests of the author, but it can also be suggested by the guides. You can have several topics, and then judge which you are most comfortable with. This may be done by asking several questions of yourself, like "Will I be able to carry out a search in this area? Will I find all necessary resources to accomplish the search? Will I be able to find all information in this field area?" If the answer to this type of question is "yes," then you ought to choose that topic. In most cases, you may have to conduct surveys and visit several places. Also, you might have to do a lot of work to find all the rises and falls of the various data on that subject. Sometimes, detailed information plays a vital role, instead of short information. Evaluators are human: The first thing to remember is that evaluators are also human beings. They are not only meant for rejecting a paper. They are here to evaluate your paper. So present your best aspect.

2. Think like evaluators: If you are in confusion or getting demotivated because your paper may not be accepted by the evaluators, then think, and try to evaluate your paper like an evaluator. Try to understand what an evaluator wants in your research paper, and you will automatically have your answer. Make blueprints of paper: The outline is the plan or framework that will help you to arrange your thoughts. It will make your paper logical. But remember that all points of your outline must be related to the topic you have chosen.

3. Ask your guides: If you are having any difficulty with your research, then do not hesitate to share your difficulty with your guide (if you have one). They will surely help you out and resolve your doubts. If you can't clarify what exactly you require for your work, then ask your supervisor to help you with an alternative. He or she might also provide you with a list of essential readings.

4. Use of computer is recommended: As you are doing research in the field of medical research then this point is quite obvious. Use right software: Always use good quality software packages. If you are not capable of judging good software, then you can lose the quality of your paper unknowingly. There are various programs available to help you which you can get through the internet.

5. Use the internet for help: An excellent start for your paper is using Google. It is a wondrous search engine, where you can have your doubts resolved. You may also read some answers for the frequent question of how to write your research paper or find a model research paper. You can download books from the internet. If you have all the required books, place importance on reading, selecting, and analyzing the specified information. Then sketch out your research paper. Use big pictures: You may use encyclopedias like Wikipedia to get pictures with the best resolution. At Global Journals, you should strictly follow here.
6. **Bookmarks are useful:** When you read any book or magazine, you generally use bookmarks, right? It is a good habit which helps to not lose your continuity. You should always use bookmarks while searching on the internet also, which will make your search easier.

7. **Revise what you wrote:** When you write anything, always read it, summarize it, and then finalize it.

8. **Make every effort:** Make every effort to mention what you are going to write in your paper. That means always have a good start. Try to mention everything in the introduction—what is the need for a particular research paper. Polish your work with good writing skills and always give an evaluator what he wants. Make backups: When you are going to do any important thing like making a research paper, you should always have backup copies of it either on your computer or on paper. This protects you from losing any portion of your important data.

9. **Produce good diagrams of your own:** Always try to include good charts or diagrams in your paper to improve quality. Using several unnecessary diagrams will degrade the quality of your paper by creating a hodgepodge. So always try to include diagrams which were made by you to improve the readability of your paper. Use of direct quotes: When you do research relevant to literature, history, or current affairs, then use of quotes becomes essential, but if the study is relevant to science, use of quotes is not preferable.

10. **Use proper verb tense:** Use proper verb tenses in your paper. Use past tense to present those events that have happened. Use present tense to indicate events that are going on. Use future tense to indicate events that will happen in the future. Use of wrong tenses will confuse the evaluator. Avoid sentences that are incomplete.

11. **Pick a good study spot:** Always try to pick a spot for your research which is quiet. Not every spot is good for studying.

12. **Know what you know:** Always try to know what you know by making objectives, otherwise you will be confused and unable to achieve your target.

13. **Use good grammar:** Always use good grammar and words that will have a positive impact on the evaluator; use of good vocabulary does not mean using tough words which the evaluator has to find in a dictionary. Do not fragment sentences. Eliminate one-word sentences. Do not ever use a big word when a smaller one would suffice. Verbs have to be in agreement with their subjects. In a research paper, do not start sentences with conjunctions or finish them with prepositions. When writing formally, it is advisable to never split an infinitive because someone will (wrongly) complain. Avoid clichés like a disease. Always shun irritating alliteration. Use language which is simple and straightforward. Put together a neat summary.

14. **Arrangement of information:** Each section of the main body should start with an opening sentence, and there should be a changeover at the end of the section. Give only valid and powerful arguments for your topic. You may also maintain your arguments with records.

15. **Never start at the last minute:** Always allow enough time for research work. Leaving everything to the last minute will degrade your paper and spoil your work.

16. **Multitasking in research is not good:** Doing several things at the same time is a bad habit in the case of research activity. Research is an area where everything has a particular time slot. Divide your research work into parts, and do a particular part in a particular time slot.

17. **Never copy others' work:** Never copy others' work and give it your name because if the evaluator has seen it anywhere, you will be in trouble. Take proper rest and food: No matter how many hours you spend on your research activity, if you are not taking care of your health, then all your efforts will have been in vain. For quality research, take proper rest and food.

18. **Go to seminars:** Attend seminars if the topic is relevant to your research area. Utilize all your resources.

19. **Refresh your mind after intervals:** Try to give your mind a rest by listening to soft music or sleeping in intervals. This will also improve your memory. Acquire colleagues: Always try to acquire colleagues. No matter how sharp you are, if you acquire colleagues, they can give you ideas which will be helpful to your research.
20. **Think technically:** Always think technically. If anything happens, search for its reasons, benefits, and demerits. Think and then print: When you go to print your paper, check that tables are not split, headings are not detached from their descriptions, and page sequence is maintained.

21. **Adding unnecessary information:** Do not add unnecessary information like "I have used MS Excel to draw graphs." Irrelevant and inappropriate material is superfluous. Foreign terminology and phrases are not apropos. One should never take a broad view. Analogy is like feathers on a snake. Use words properly, regardless of how others use them. Remove quotations. Puns are for kids, not grunt readers. Never oversimplify: When adding material to your research paper, never go for oversimplification; this will definitely irritate the evaluator. Be specific. Never use rhythmic redundancies. Contractions shouldn’t be used in a research paper. Comparisons are as terrible as clichés. Give up ampersands, abbreviations, and so on. Remove commas that are not necessary. Parenthetical words should be between brackets or commas. Understatement is always the best way to put forward earth-shaking thoughts. Give a detailed literary review.

22. **Report concluded results:** Use concluded results. From raw data, filter the results, and then conclude your studies based on measurements and observations taken. An appropriate number of decimal places should be used. Parenthetical remarks are prohibited here. Proofread carefully at the final stage. At the end, give an outline to your arguments. Spot perspectives of further study of the subject. Justify your conclusion at the bottom sufficiently, which will probably include examples.

23. **Upon conclusion:** Once you have concluded your research, the next most important step is to present your findings. Presentation is extremely important as it is the definite medium through which your research is going to be in print for the rest of the crowd. Care should be taken to categorize your thoughts well and present them in a logical and neat manner. A good quality research paper format is essential because it serves to highlight your research paper and bring to light all necessary aspects of your research.

### Informal Guidelines of Research Paper Writing

**Key points to remember:**
- Submit all work in its final form.
- Write your paper in the form which is presented in the guidelines using the template.
- Please note the criteria peer reviewers will use for grading the final paper.

**Final points:**

One purpose of organizing a research paper is to let people interpret your efforts selectively. The journal requires the following sections, submitted in the order listed, with each section starting on a new page:

**The introduction:** This will be compiled from reference matter and reflect the design processes or outline of basis that directed you to make a study. As you carry out the process of study, the method and process section will be constructed like that. The results segment will show related statistics in nearly sequential order and direct reviewers to similar intellectual paths throughout the data that you gathered to carry out your study.

**The discussion section:**

This will provide understanding of the data and projections as to the implications of the results. The use of good quality references throughout the paper will give the effort trustworthiness by representing an alertness to prior workings.

Writing a research paper is not an easy job, no matter how trouble-free the actual research or concept. Practice, excellent preparation, and controlled record-keeping are the only means to make straightforward progression.

**General style:**

Specific editorial column necessities for compliance of a manuscript will always take over from directions in these general guidelines.

**To make a paper clear:** Adhere to recommended page limits.
**Mistakes to avoid:**

- Insertion of a title at the foot of a page with subsequent text on the next page.
- Separating a table, chart, or figure—confine each to a single page.
- Submitting a manuscript with pages out of sequence.
- In every section of your document, use standard writing style, including articles ("a" and "the").
- Keep paying attention to the topic of the paper.
- Use paragraphs to split each significant point (excluding the abstract).
- Align the primary line of each section.
- Present your points in sound order.
- Use present tense to report well-accepted matters.
- Use past tense to describe specific results.
- Do not use familiar wording; don't address the reviewer directly. Don't use slang or superlatives.
- Avoid use of extra pictures—including only those figures essential to presenting results.

**Title page:**

Choose a revealing title. It should be short and include the name(s) and address(es) of all authors. It should not have acronyms or abbreviations or exceed two printed lines.

**Abstract:** This summary should be two hundred words or less. It should clearly and briefly explain the key findings reported in the manuscript and must have precise statistics. It should not have acronyms or abbreviations. It should be logical in itself. Do not cite references at this point.

An abstract is a brief, distinct paragraph summary of finished work or work in development. In a minute or less, a reviewer can be taught the foundation behind the study, common approaches to the problem, relevant results, and significant conclusions or new questions.

Write your summary when your paper is completed because how can you write the summary of anything which is not yet written? Wealth of terminology is very essential in abstract. Use comprehensive sentences, and do not sacrifice readability for brevity; you can maintain it succinctly by phrasing sentences so that they provide more than a lone rationale. The author can at this moment go straight to shortening the outcome. Sum up the study with the subsequent elements in any summary. Try to limit the initial two items to no more than one line each.

**Reason for writing the article—theory, overall issue, purpose.**

- Fundamental goal.
- To-the-point depiction of the research.
- Consequences, including definite statistics—if the consequences are quantitative in nature, account for this; results of any numerical analysis should be reported. Significant conclusions or questions that emerge from the research.

**Approach:**

- Single section and succinct.
- An outline of the job done is always written in past tense.
- Concentrate on shortening results—limit background information to a verdict or two.
- Exact spelling, clarity of sentences and phrases, and appropriate reporting of quantities (proper units, important statistics) are just as significant in an abstract as they are anywhere else.

**Introduction:**

The introduction should "introduce" the manuscript. The reviewer should be presented with sufficient background information to be capable of comprehending and calculating the purpose of your study without having to refer to other works. The basis for the study should be offered. Give the most important references, but avoid making a comprehensive appraisal of the topic. Describe the problem visibly. If the problem is not acknowledged in a logical, reasonable way, the reviewer will give no attention to your results. Speak in common terms about techniques used to explain the problem, if needed, but do not present any particulars about the protocols here.

© Copyright by Global Journals | Guidelines Handbook
The following approach can create a valuable beginning:

- Explain the value (significance) of the study.
- Defend the model—why did you employ this particular system or method? What is its compensation? Remark upon its appropriateness from an abstract point of view as well as pointing out sensible reasons for using it.
- Present a justification. State your particular theory(-ies) or aim(s), and describe the logic that led you to choose them.
- Briefly explain the study's tentative purpose and how it meets the declared objectives.

Approach:

Use past tense except for when referring to recognized facts. After all, the manuscript will be submitted after the entire job is done. Sort out your thoughts; manufacture one key point for every section. If you make the four points listed above, you will need at least four paragraphs. Present surrounding information only when it is necessary to support a situation. The reviewer does not desire to read everything you know about a topic. Shape the theory specifically—do not take a broad view.

As always, give awareness to spelling, simplicity, and correctness of sentences and phrases.

Procedures (methods and materials):

This part is supposed to be the easiest to carve if you have good skills. A soundly written procedures segment allows a capable scientist to replicate your results. Present precise information about your supplies. The suppliers and clarity of reagents can be helpful bits of information. Present methods in sequential order, but linked methodologies can be grouped as a segment. Be concise when relating the protocols. Attempt to give the least amount of information that would permit another capable scientist to replicate your outcome, but be cautious that vital information is integrated. The use of subheadings is suggested and ought to be synchronized with the results section.

When a technique is used that has been well-described in another section, mention the specific item describing the way, but draw the basic principle while stating the situation. The purpose is to show all particular resources and broad procedures so that another person may use some or all of the methods in one more study or referee the scientific value of your work. It is not to be a step-by-step report of the whole thing you did, nor is a methods section a set of orders.

Materials:

Materials may be reported in part of a section or else they may be recognized along with your measures.

Methods:

- Report the method and not the particulars of each process that engaged the same methodology.
- Describe the method entirely.
- To be succinct, present methods under headings dedicated to specific dealings or groups of measures.
- Simplify—detail how procedures were completed, not how they were performed on a particular day.
- If well-known procedures were used, account for the procedure by name, possibly with a reference, and that's all.

Approach:

It is embarrassing to use vigorous voice when documenting methods without using first person, which would focus the reviewer’s interest on the researcher rather than the job. As a result, when writing up the methods, most authors use third person passive voice.

Use standard style in this and every other part of the paper—avoid familiar lists, and use full sentences.

What to keep away from:

- Resources and methods are not a set of information.
- Skip all descriptive information and surroundings—save it for the argument.
- Leave out information that is immaterial to a third party.
Results:
The principle of a results segment is to present and demonstrate your conclusion. Create this part as entirely objective
details of the outcome, and save all understanding for the discussion.
The page length of this segment is set by the sum and types of data to be reported. Use statistics and tables, if suitable, to
present consequences most efficiently.
You must clearly differentiate material which would usually be incorporated in a study editorial from any unprocessed data
or additional appendix matter that would not be available. In fact, such matters should not be submitted at all except if
requested by the instructor.

Content:
- Sum up your conclusions in text and demonstrate them, if suitable, with figures and tables.
- In the manuscript, explain each of your consequences, and point the reader to remarks that are most appropriate.
- Present a background, such as by describing the question that was addressed by creation of an exacting study.
- Explain results of control experiments and give remarks that are not accessible in a prescribed figure or table, if
  appropriate.
- Examine your data, then prepare the analyzed (transformed) data in the form of a figure (graph), table, or
  manuscript.

What to stay away from:
- Do not discuss or infer your outcome, report surrounding information, or try to explain anything.
- Do not include raw data or intermediate calculations in a research manuscript.
- Do not present similar data more than once.
- A manuscript should complement any figures or tables, not duplicate information.
- Never confuse figures with tables—there is a difference.

Approach:
As always, use past tense when you submit your results, and put the whole thing in a reasonable order.
Put figures and tables, appropriately numbered, in order at the end of the report.
If you desire, you may place your figures and tables properly within the text of your results section.

Figures and tables:
If you put figures and tables at the end of some details, make certain that they are visibly distinguished from any attached
appendix materials, such as raw facts. Whatever the position, each table must be titled, numbered one after the other, and
include a heading. All figures and tables must be divided from the text.

Discussion:
The discussion is expected to be the trickiest segment to write. A lot of papers submitted to the journal are discarded
based on problems with the discussion. There is no rule for how long an argument should be.
Position your understanding of the outcome visibly to lead the reviewer through your conclusions, and then finish the
paper with a summing up of the implications of the study. The purpose here is to offer an understanding of your results
and support all of your conclusions, using facts from your research and generally accepted information, if suitable. The
implication of results should be fully described.
Infer your data in the conversation in suitable depth. This means that when you clarify an observable fact, you must explain
mechanisms that may account for the observation. If your results vary from your prospect, make clear why that may have
happened. If your results agree, then explain the theory that the proof supported. It is never suitable to just state that the
data approved the prospect, and let it drop at that. Make a decision as to whether each premise is supported or discarded
or if you cannot make a conclusion with assurance. Do not just dismiss a study or part of a study as "uncertain."
Research papers are not acknowledged if the work is imperfect. Draw what conclusions you can based upon the results that you have, and take care of the study as a finished work.

- You may propose future guidelines, such as how an experiment might be personalized to accomplish a new idea.
- Give details of all of your remarks as much as possible, focusing on mechanisms.
- Make a decision as to whether the tentative design sufficiently addressed the theory and whether or not it was correctly restricted. Try to present substitute explanations if they are sensible alternatives.
- One piece of research will not counter an overall question, so maintain the large picture in mind. Where do you go next? The best studies unlock new avenues of study. What questions remain?
- Recommendations for detailed papers will offer supplementary suggestions.

**Approach:**

When you refer to information, differentiate data generated by your own studies from other available information. Present work done by specific persons (including you) in past tense.

Describe generally acknowledged facts and main beliefs in present tense.

**The Administration Rules**

Administration Rules to Be Strictly Followed before Submitting Your Research Paper to Global Journals Inc.

*Please read the following rules and regulations carefully before submitting your research paper to Global Journals Inc. to avoid rejection.*

*Segment draft and final research paper:* You have to strictly follow the template of a research paper, failing which your paper may get rejected. You are expected to write each part of the paper wholly on your own. The peer reviewers need to identify your own perspective of the concepts in your own terms. Please do not extract straight from any other source, and do not rephrase someone else's analysis. Do not allow anyone else to proofread your manuscript.

*Written material:* You may discuss this with your guides and key sources. Do not copy anyone else’s paper, even if this is only imitation, otherwise it will be rejected on the grounds of plagiarism, which is illegal. Various methods to avoid plagiarism are strictly applied by us to every paper, and, if found guilty, you may be blacklisted, which could affect your career adversely. To guard yourself and others from possible illegal use, please do not permit anyone to use or even read your paper and file.
Please note that following table is only a Grading of "Paper Compilation" and not on "Performed/Stated Research" whose grading solely depends on Individual Assigned Peer Reviewer and Editorial Board Member. These can be available only on request and after decision of Paper. This report will be the property of Global Journals.

<table>
<thead>
<tr>
<th>Topics</th>
<th>Grades</th>
<th>A-B</th>
<th>C-D</th>
<th>E-F</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract</td>
<td></td>
<td>Clear and concise with appropriate content, Correct format. 200 words or below</td>
<td>Unclear summary and no specific data, Incorrect form Above 200 words</td>
<td>No specific data with ambiguous information Above 250 words</td>
</tr>
<tr>
<td>Introduction</td>
<td></td>
<td>Containing all background details with clear goal and appropriate details, flow specification, no grammar and spelling mistake, well organized sentence and paragraph, reference cited</td>
<td>Unclear and confusing data, appropriate format, grammar and spelling errors with unorganized matter</td>
<td>Out of place depth and content, hazy format</td>
</tr>
<tr>
<td>Methods and Procedures</td>
<td></td>
<td>Clear and to the point with well arranged paragraph, precision and accuracy of facts and figures, well organized subheads</td>
<td>Difficult to comprehend with embarrassed text, too much explanation but completed</td>
<td>Incorrect and unorganized structure with hazy meaning</td>
</tr>
<tr>
<td>Result</td>
<td></td>
<td>Well organized, Clear and specific, Correct units with precision, correct data, well structuring of paragraph, no grammar and spelling mistake</td>
<td>Complete and embarrassed text, difficult to comprehend</td>
<td>Irregular format with wrong facts and figures</td>
</tr>
<tr>
<td>Discussion</td>
<td></td>
<td>Well organized, meaningful specification, sound conclusion, logical and concise explanation, highly structured paragraph reference cited</td>
<td>Wordy, unclear conclusion, spurious</td>
<td>Conclusion is not cited, unorganized, difficult to comprehend</td>
</tr>
<tr>
<td>References</td>
<td></td>
<td>Complete and correct format, well organized</td>
<td>Beside the point, Incomplete</td>
<td>Wrong format and structuring</td>
</tr>
</tbody>
</table>
INDEX

A
Alimentation · 16

C
Chromaticity · 2

D
Deglutition · 12, 16
Distortion · 23, 28, 30, 31, 32, 33, 37

E
Enormous · 19

I
Improbable · 19
Infusions · 1, 6

O
Opacity · 26

P
Particulate · 5
Precipitate · 2
Precision · 7, 9, 10